{
  "meta": {
    "id": "test46",
    "title": "Late Night PYQ_PYT Marathon (OBG-6) - 2025-03-07",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Match the following syndromes with their respective karyotypes? (INICET NOV 2021)",
      "options": [
        {
          "label": "A",
          "text": "1-A, 2-B, 3-D, 4-C",
          "correct": true
        },
        {
          "label": "B",
          "text": "\ufeff\ufeff\ufeff1-B, 2-C, 3-D, 4-A",
          "correct": false
        },
        {
          "label": "C",
          "text": "\ufeff\ufeff\ufeff1-A, 2-B, 3-C, 4-D",
          "correct": false
        },
        {
          "label": "D",
          "text": "\ufeff\ufeff\ufeff1-D, 2-A, 3-C, 4-B",
          "correct": false
        }
      ],
      "correct_answer": "A. 1-A, 2-B, 3-D, 4-C",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/14/screenshot-2024-10-14-185037.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 1-A, 2-B, 3-D, 4-C</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 MRKH syndrome (Mayer-Rokitansky-K\u00fcster-Hauser): This syndrome has a karyotype of 46XX . Swyer Syndrome: This condition is characterized by 46XY karyotype. Turner Syndrome: This is due to monosomy X, having a karyotype of 45XO . Androgen Insensitivity Syndrome: This condition occurs in individuals with a karyotype of 46XY , where there is a complete androgen insensitivity, resulting in a phenotypically female appearance despite having male (XY) chromosomes.</li><li>\u2022 MRKH syndrome (Mayer-Rokitansky-K\u00fcster-Hauser): This syndrome has a karyotype of 46XX .</li><li>\u2022 MRKH syndrome (Mayer-Rokitansky-K\u00fcster-Hauser):</li><li>\u2022 46XX</li><li>\u2022 Swyer Syndrome: This condition is characterized by 46XY karyotype.</li><li>\u2022 Swyer Syndrome:</li><li>\u2022 46XY</li><li>\u2022 Turner Syndrome: This is due to monosomy X, having a karyotype of 45XO .</li><li>\u2022 Turner Syndrome:</li><li>\u2022 45XO</li><li>\u2022 Androgen Insensitivity Syndrome: This condition occurs in individuals with a karyotype of 46XY , where there is a complete androgen insensitivity, resulting in a phenotypically female appearance despite having male (XY) chromosomes.</li><li>\u2022 Androgen Insensitivity Syndrome:</li><li>\u2022 46XY</li><li>\u2022 Matching:</li><li>\u2022 Matching:</li><li>\u2022 MRKH : 46XX Swyer Syndrome : 46XY Turner Syndrome : 45XO Androgen Insensitivity Syndrome : 46XY</li><li>\u2022 MRKH : 46XX</li><li>\u2022 MRKH</li><li>\u2022 Swyer Syndrome : 46XY</li><li>\u2022 Swyer Syndrome</li><li>\u2022 Turner Syndrome : 45XO</li><li>\u2022 Turner Syndrome</li><li>\u2022 Androgen Insensitivity Syndrome : 46XY</li><li>\u2022 Androgen Insensitivity Syndrome</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Understanding the karyotypes associated with different syndromes helps in diagnosing and managing these conditions effectively. MRKH is associated with 46XX, Swyer syndrome with 46XY, Turner syndrome with 45XO, and Androgen Insensitivity Syndrome with 46XY.</li><li>\u27a4 Ref: Dutta\u2019s textbook of gynecology 6 th edition pg 446,447</li><li>\u27a4 Ref: Dutta\u2019s textbook of gynecology 6 th edition pg 446,447</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d9d8a7f7",
      "audio": ""
    },
    {
      "text": "The maximum dose of PGF2 alpha in postpartum hemorrhage is? (NEET PG 2019)",
      "options": [
        {
          "label": "A",
          "text": "0.25 mg",
          "correct": false
        },
        {
          "label": "B",
          "text": "2 mg",
          "correct": true
        },
        {
          "label": "C",
          "text": "20 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "200 mg",
          "correct": false
        }
      ],
      "correct_answer": "B. 2 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 2 mg</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Prostaglandin F2 alpha (PGF2\u03b1), also known as carboprost, is used for the treatment of postpartum hemorrhage (PPH) due to uterine atony. The therapeutic regimen and maximum dosage are crucial for effective management and patient safety.</li><li>\u2022 Dose and Administration: The approved dose for treating uterine atony with PGF2\u03b1 is 0.25 mg administered intramuscularly (IM). Maximum Dose: The maximum cumulative dose is 2 mg. This is achieved by administering a total of 8 doses of 0.25 mg each. Dosing Interval: These doses can be repeated at intervals of 15 to 90 minutes, depending on the clinical response and the patient's condition.</li><li>\u2022 Dose and Administration: The approved dose for treating uterine atony with PGF2\u03b1 is 0.25 mg administered intramuscularly (IM).</li><li>\u2022 Dose and Administration:</li><li>\u2022 Maximum Dose: The maximum cumulative dose is 2 mg. This is achieved by administering a total of 8 doses of 0.25 mg each.</li><li>\u2022 Maximum Dose:</li><li>\u2022 Dosing Interval: These doses can be repeated at intervals of 15 to 90 minutes, depending on the clinical response and the patient's condition.</li><li>\u2022 Dosing Interval:</li><li>\u2022 Contraindications</li><li>\u2022 Contraindications</li><li>\u2022 Bronchial Asthma: PGF2\u03b1 can cause bronchoconstriction, which makes it contraindicated in patients with bronchial asthma. Suspected Amniotic Fluid Embolism: Due to its potential to cause pulmonary airway and vascular constriction, it is also contraindicated in cases of suspected amniotic fluid embolism.</li><li>\u2022 Bronchial Asthma: PGF2\u03b1 can cause bronchoconstriction, which makes it contraindicated in patients with bronchial asthma.</li><li>\u2022 Bronchial Asthma:</li><li>\u2022 Suspected Amniotic Fluid Embolism: Due to its potential to cause pulmonary airway and vascular constriction, it is also contraindicated in cases of suspected amniotic fluid embolism.</li><li>\u2022 Suspected Amniotic Fluid Embolism:</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. 0.25 mg : This is the single dose administered IM but not the cumulative maximum dose.</li><li>\u2022 Option A. 0.25 mg</li><li>\u2022 Option C. 20 mg : This dose is excessively high and not clinically recommended or safe.</li><li>\u2022 Option C. 20 mg</li><li>\u2022 Option D. 200 mg : This dose is not applicable for human use and is far beyond the safe and recommended limits.</li><li>\u2022 Option D. 200 mg</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The maximum dose of prostaglandin F2 alpha in the management of postpartum hemorrhage is 2 mg, administered in 0.25 mg increments intramuscularly.</li><li>\u27a4 Ref: Page no 480, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li><li>\u27a4 Ref: Page no 480, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "91b16d68",
      "audio": ""
    },
    {
      "text": "Identify the blue-colored area shown in the image below? (NEET PG 2022)",
      "options": [
        {
          "label": "A",
          "text": "Obstetric outlet",
          "correct": false
        },
        {
          "label": "B",
          "text": "\ufeff\ufeff\ufeffAnatomical outlet",
          "correct": false
        },
        {
          "label": "C",
          "text": "\ufeff\ufeff\ufeffPelvic inlet",
          "correct": false
        },
        {
          "label": "D",
          "text": "\ufeff\ufeff\ufeffMid-pelvis",
          "correct": true
        }
      ],
      "correct_answer": "D. \ufeff\ufeff\ufeffMid-pelvis",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/untitled-85.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Mid-pelvis</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The plane of the mid-pelvis (or mid cavity) is a crucial area within the true pelvis, significant for various clinical considerations during labor and delivery.</li><li>\u27a4 Ref: Page no 92 Textbook of obstetrics by JB Sharma</li><li>\u27a4 Ref: Page no 92 Textbook of obstetrics by JB Sharma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "140fd7cc",
      "audio": ""
    },
    {
      "text": "All the following are indications of caesarean section except? (FMGE JAN 2023)",
      "options": [
        {
          "label": "A",
          "text": "Previous history of macrosomia",
          "correct": true
        },
        {
          "label": "B",
          "text": "Absolute Cephalopelvic disproportion",
          "correct": false
        },
        {
          "label": "C",
          "text": "Central placenta previa",
          "correct": false
        },
        {
          "label": "D",
          "text": "Advanced CA cervix",
          "correct": false
        }
      ],
      "correct_answer": "A. Previous history of macrosomia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/19/untitled-1040.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Previous history of macrosomia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Options B, C and D are Absolute Indications for caesarean section. It means vaginal delivery is not possible</li><li>\u2022 Options B, C</li><li>\u2022 D</li><li>\u2022 Absolute indications for caesarean section include:</li><li>\u2022 Absolute indications</li><li>\u2022 Central placenta praevia Contracted pelvis or CPD Pelvic mass causing obstruction Advanced CA cervix Vaginal obstruction (atresia, stenosis)</li><li>\u2022 Central placenta praevia</li><li>\u2022 Contracted pelvis or CPD</li><li>\u2022 Pelvic mass causing obstruction</li><li>\u2022 Advanced CA cervix</li><li>\u2022 Vaginal obstruction (atresia, stenosis)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Previous history of macrosomia is not an indication for caesarean section.</li><li>\u27a4 Previous history of macrosomia is not an indication for</li><li>\u27a4 Ref: Dutta\u2019s textbook of obstetrics page 670</li><li>\u27a4 Ref: Dutta\u2019s textbook of obstetrics page 670</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dbf82105",
      "audio": ""
    },
    {
      "text": "A 52-year-old woman came to the OPD with a diagnosis of advanced cervical cancer. She has a 14-year-old daughter. What advice would you give for her daughter? (NEET PG 2023)",
      "options": [
        {
          "label": "A",
          "text": "Advise HPV vaccine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Screen for BRCA mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Screen for PTEN mutation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Perform cervical biopsy",
          "correct": false
        }
      ],
      "correct_answer": "A. Advise HPV vaccine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Advise HPV vaccine</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The HPV vaccine is essential for preventing cervical cancer and should be administered to girls aged 9 to 14 years, ideally before the onset of sexual activity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "37ec38bb",
      "audio": ""
    },
    {
      "text": "Fimbriectomy is also known as? (NEET PG 2018)",
      "options": [
        {
          "label": "A",
          "text": "Pomeroy technique",
          "correct": false
        },
        {
          "label": "B",
          "text": "Uchida's procedure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Kroner's procedure",
          "correct": true
        },
        {
          "label": "D",
          "text": "Irving's procedure",
          "correct": false
        }
      ],
      "correct_answer": "C. Kroner's procedure",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Kroner\u2019s procedure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Fimbriectomy is a method of tubal ligation where the fimbriated end of the Fallopian tube is ligated and excised. This technique is also known as Kroner\u2019s procedure.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Pomeroy technique : In this method, the mid-isthmic portion of the Fallopian tube is elevated and then folded at the midpoint. One or two rapidly absorbable sutures are tied around the double thickness of the tube, and the folded portion is excised sharply.</li><li>\u2022 Option A. Pomeroy technique</li><li>\u2022 Option B. Uchida's procedure : This involves ligating and excising the midportion of the Fallopian tube. The utero-tubal serosa is then hydro-dissected, and the proximal tubal stump is pulled into the mesosalpinx. The peritoneum is closed over the proximal cut end of the tube.</li><li>\u2022 Option B. Uchida's procedure</li><li>\u2022 Option D. Irving's procedure : In this method, the midportion of the Fallopian tube is ligated and excised. The proximal tubal stump is inserted into an incision made into the myometrium and securely sutured to bury the proximal stump in the myometrium.</li><li>\u2022 Option D. Irving's procedure</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fimbriectomy, also known as Kroner's procedure, involves ligation and excision of the fimbriated end of the Fallopian tube.</li><li>\u27a4 Ref: Page no 497, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li><li>\u27a4 Ref: Page no 497, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b557f4c3",
      "audio": ""
    },
    {
      "text": "Which hormone is secreted by placenta? (INICET NOV 2022)",
      "options": [
        {
          "label": "A",
          "text": "LH",
          "correct": false
        },
        {
          "label": "B",
          "text": "hCG",
          "correct": true
        },
        {
          "label": "C",
          "text": "FSH",
          "correct": false
        },
        {
          "label": "D",
          "text": "GnRH",
          "correct": false
        }
      ],
      "correct_answer": "B. hCG",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) hCG</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Human chorionic gonadotropin (hCG) is the hormone secreted by the placenta. It is a glycoprotein produced by the syncytiotrophoblast cells of the placenta. hCG can be detected in the maternal serum or urine as early as 8-9 days post-fertilization using radioimmunoassay. In early pregnancy, hCG concentrations in plasma double every 1.4-2 days. The primary role of hCG is to maintain the corpus luteum during the beginning of pregnancy, ensuring the continued production of progesterone, which is critical for maintaining the uterine lining and supporting pregnancy.</li><li>\u2022 Human chorionic gonadotropin (hCG) is the hormone secreted by the placenta. It is a glycoprotein produced by the syncytiotrophoblast cells of the placenta.</li><li>\u2022 Human chorionic gonadotropin (hCG)</li><li>\u2022 hCG can be detected in the maternal serum or urine as early as 8-9 days post-fertilization using radioimmunoassay. In early pregnancy, hCG concentrations in plasma double every 1.4-2 days.</li><li>\u2022 The primary role of hCG is to maintain the corpus luteum during the beginning of pregnancy, ensuring the continued production of progesterone, which is critical for maintaining the uterine lining and supporting pregnancy.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. LH : Luteinizing Hormone is produced by the anterior pituitary gland, not by the placenta. It plays a key role in regulating the menstrual cycle and ovulation.</li><li>\u2022 Option A. LH</li><li>\u2022 Option C. FSH : Follicle-Stimulating Hormone is also produced by the anterior pituitary gland. It is involved in the development of ovarian follicles and the regulation of the menstrual cycle.</li><li>\u2022 Option C. FSH</li><li>\u2022 Option D. GnRH : Gonadotropin-Releasing Hormone is produced by the hypothalamus, it stimulates the anterior pituitary gland to release FSH and LH.</li><li>\u2022 Option D. GnRH</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Human chorionic gonadotropin (hCG) is a hormone secreted by the placenta, crucial for maintaining early pregnancy by supporting the corpus luteum and progesterone production.</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 26 th edition pg266, Dutta\u2019s textbook of obstetrics 8 th edition pg 66</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 26 th edition pg266, Dutta\u2019s textbook of obstetrics 8 th edition pg 66</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "98d5cef0",
      "audio": ""
    },
    {
      "text": "Antepartum hemorrhage due to abruption shows all except? (INICET NOV 2022)",
      "options": [
        {
          "label": "A",
          "text": "Uterine tenderness",
          "correct": false
        },
        {
          "label": "B",
          "text": "Frequent contractions",
          "correct": false
        },
        {
          "label": "C",
          "text": "Painless vaginal bleeding",
          "correct": true
        },
        {
          "label": "D",
          "text": "Mild to moderate vaginal bleeding",
          "correct": false
        }
      ],
      "correct_answer": "C. Painless vaginal bleeding",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Painless vaginal bleeding</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Painless vaginal bleeding is not a feature of abruption of the placenta. It is a characteristic feature of placenta previa. Patients with placental abruption present with sudden-onset abdominal pain, vaginal bleeding, uterine tenderness, and frequent contractions. Abruptio placenta is the partial or total separation of a normally implanted placenta before delivery, leading to bleeding and other complications.</li><li>\u2022 Painless vaginal bleeding is not a feature of abruption of the placenta. It is a characteristic feature of placenta previa.</li><li>\u2022 Painless vaginal bleeding</li><li>\u2022 Patients with placental abruption present with sudden-onset abdominal pain, vaginal bleeding, uterine tenderness, and frequent contractions.</li><li>\u2022 Abruptio placenta is the partial or total separation of a normally implanted placenta before delivery, leading to bleeding and other complications.</li><li>\u2022 Abruptio placenta</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Uterine tenderness : This is a common feature of placental abruption due to the separation of the placenta from the uterine wall.</li><li>\u2022 Option A. Uterine tenderness</li><li>\u2022 Option B. Frequent contractions : Increased frequency of uterine contractions is associated with placental abruption.</li><li>\u2022 Option B. Frequent contractions</li><li>\u2022 Option D. Mild to moderate vaginal bleeding : Vaginal bleeding of varying degrees, from mild to severe, is typically seen in placental abruption.</li><li>\u2022 Option D. Mild to moderate vaginal bleeding</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Placental abruption presents with sudden-onset abdominal pain, vaginal bleeding, uterine tenderness, and frequent contractions, but not with painless vaginal bleeding, which is characteristic of placenta previa.</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 26 th edition pg1944,  Dutta\u2019s textbook of obstetrics 8 th edition pg 297</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 26 th edition pg1944,  Dutta\u2019s textbook of obstetrics 8 th edition pg 297</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e00612cd",
      "audio": ""
    },
    {
      "text": "A woman with 31 weeks of gestation presents with lower abdominal pain. The clinician is concerned if the patient is in preterm labor. Which of the following is the most appropriate test in this scenario? (INICET NOV 2018)",
      "options": [
        {
          "label": "A",
          "text": "Alpha fetoprotein",
          "correct": false
        },
        {
          "label": "B",
          "text": "Beta HCG",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fetal fibronectin",
          "correct": true
        },
        {
          "label": "D",
          "text": "PAPP-A",
          "correct": false
        }
      ],
      "correct_answer": "C. Fetal fibronectin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Fetal fibronectin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Fetal fibronectin (fFN) is a glycoprotein produced by fetal amnion cells and found in high concentrations in amniotic fluid. It is also found in cervico-vaginal secretions in early pregnancy (less than 22 weeks) and late pregnancy (greater than 37 weeks). The presence of fFN in cervico-vaginal secretions between 22 and 37 weeks is used as a predictor of preterm labor.</li><li>\u2022 A fFN level greater than 50 ng/mL is considered a significant predictor of preterm labor. The American College of Obstetricians and Gynecologists (ACOG) does not recommend routine use of fFN testing but it can be helpful in specific clinical scenarios where preterm labor is suspected.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Alpha fetoprotein: Alpha fetoprotein (AFP) is used in prenatal screening for neural tube defects and as a component of the quadruple marker test for Down syndrome. Elevated AFP levels are associated with neural tube defects, while decreased levels can indicate Down syndrome.</li><li>\u2022 Option A. Alpha fetoprotein:</li><li>\u2022 Option B. Beta HCG: Beta HCG is used in early pregnancy for confirming pregnancy and in first trimester screening for Down syndrome (where levels are elevated). It is not used for diagnosing preterm labor.</li><li>\u2022 Option B. Beta HCG:</li><li>\u2022 Option D. PAPP-A: Pregnancy-associated plasma protein-A (PAPP-A) is used in first trimester screening for Down syndrome, where its levels are decreased. It is not used for diagnosing preterm labor.</li><li>\u2022 Option D. PAPP-A:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fetal fibronectin (fFN) testing is the most appropriate test for assessing the risk of preterm labor in a woman presenting with lower abdominal pain at 31 weeks of gestation. A positive fFN test (greater than 50 ng/mL) can help predict the likelihood of preterm labor.</li><li>\u27a4 Ref: Dutta\u2019s textbook of obstetrics 8 th edition pg 366</li><li>\u27a4 Ref: Dutta\u2019s textbook of obstetrics 8 th edition pg 366</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "296dd60d",
      "audio": ""
    },
    {
      "text": "A 15-year-old girl comes in with primary amenorrhea and indications of virilization. She displays underdeveloped breasts and pubic hair consistent with prepubertal stages, rated at Tanner stage 2. She has a closed-off vaginal canal and noticeable enlargement of the clitoris. Despite her female sex, her testosterone levels are within the male range. Her genetic makeup is 46XY. What is the likely medical diagnosis in this case? (INICET MAY 2023)",
      "options": [
        {
          "label": "A",
          "text": "5 alpha reductase deficiency",
          "correct": true
        },
        {
          "label": "B",
          "text": "17 alpha hydroxylase deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Androgen insensitivity syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Swyer syndrome",
          "correct": false
        }
      ],
      "correct_answer": "A. 5 alpha reductase deficiency",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/15/whatsapp-image-2023-06-12-at-190121011010201026_page_49.jpg"
      ],
      "explanation": "<p><strong>Ans. A) 5 alpha reductase deficiency</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The given scenario points to a diagnosis of 5 alpha reductase deficiency.</li><li>\u2022 5 alpha reductase deficiency causes inability to convert testosterone to DHT.</li><li>\u2022 When DHT levels are low, newborns will possess external genitalia with a feminine appearance. These youngsters are commonly brought up as girls until they reach puberty, at which point they begin to display signs of masculinization due to the influence of testosterone. As a result, clitoromegaly becomes evident. The absence of estrogen conversion from testosterone results in limited breast growth. Scanty pubic hair is observed since its growth is contingent on both testosterone and dihydrotestosterone.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. 17 alpha hydroxylase deficiency : Leads to reduced formation of corticosteroids, sex hormones and increased mineralocorticoids (causing hypokalemia and hypertension). Patient with XY chromosome presents with atypical genitalia and undescended testes. Patient with XX chromosome lacks secondary sexual development.</li><li>\u2022 Option B. 17 alpha hydroxylase deficiency</li><li>\u2022 Option C. Androgen insensitivity syndrome : Defect in androgen receptor resulting in female-appearing genetic male (46, XY); female external genitalia with scant axillary and pubic hair, rudimentary vagina; uterus and fallopian tubes absent due to persistence of anti-Mullerian hormone from testes. Patients develop normal functioning testes. Patient has increased testosterone, estrogen & LH as compared to other sex chromosome disorders.</li><li>\u2022 Option C. Androgen insensitivity syndrome</li><li>\u2022 Option D. Swyer syndrome : 46 XY gonadal dysgenesis; Absent secondary sexual characters, but normal female internal and external genitalia. Gonadectomy needs to be done.</li><li>\u2022 Option D. Swyer syndrome</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 5-alpha reductase deficiency causes primary amenorrhea and virilization in genetic females (46XY), resulting in the inability to convert testosterone to dihydrotestosterone (DHT). This leads to female external genitalia at birth and masculinization at puberty, with signs such as clitoromegaly and underdeveloped breasts.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "65906f34",
      "audio": ""
    },
    {
      "text": "Gestational trophoblastic neoplasm does not include? (NEET PG 2019)",
      "options": [
        {
          "label": "A",
          "text": "Partial mole",
          "correct": true
        },
        {
          "label": "B",
          "text": "Choriocarcinoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Placental site trophoblastic tumor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Invasive mole",
          "correct": false
        }
      ],
      "correct_answer": "A. Partial mole",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Partial mole</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Gestational trophoblastic disease (GTD) includes a spectrum of conditions characterized by abnormal trophoblastic proliferation. These conditions are broadly classified into molar and non-molar trophoblastic diseases.</li><li>\u2022 Hydatidiform Mole: Complete Mole Partial Mole Invasive Mole Non-Molar Trophoblastic Diseases: Choriocarcinoma Placental Site Trophoblastic Tumor Epithelioid Trophoblastic Tumor</li><li>\u2022 Hydatidiform Mole: Complete Mole Partial Mole Invasive Mole</li><li>\u2022 Hydatidiform Mole:</li><li>\u2022 Complete Mole Partial Mole Invasive Mole</li><li>\u2022 Complete Mole</li><li>\u2022 Complete Mole</li><li>\u2022 Partial Mole</li><li>\u2022 Partial Mole</li><li>\u2022 Invasive Mole</li><li>\u2022 Invasive Mole</li><li>\u2022 Non-Molar Trophoblastic Diseases: Choriocarcinoma Placental Site Trophoblastic Tumor Epithelioid Trophoblastic Tumor</li><li>\u2022 Non-Molar Trophoblastic Diseases:</li><li>\u2022 Choriocarcinoma Placental Site Trophoblastic Tumor Epithelioid Trophoblastic Tumor</li><li>\u2022 Choriocarcinoma</li><li>\u2022 Choriocarcinoma</li><li>\u2022 Placental Site Trophoblastic Tumor</li><li>\u2022 Placental Site Trophoblastic Tumor</li><li>\u2022 Epithelioid Trophoblastic Tumor</li><li>\u2022 Epithelioid Trophoblastic Tumor</li><li>\u2022 Gestational Trophoblastic Neoplasia (GTN) , on the other hand, includes only the malignant forms of trophoblastic disease:</li><li>\u2022 Gestational Trophoblastic Neoplasia (GTN)</li><li>\u2022 Invasive Mole Choriocarcinoma Placental Site Trophoblastic Tumor Epithelioid Trophoblastic Tumor</li><li>\u2022 Invasive Mole</li><li>\u2022 Invasive Mole</li><li>\u2022 Choriocarcinoma</li><li>\u2022 Choriocarcinoma</li><li>\u2022 Placental Site Trophoblastic Tumor</li><li>\u2022 Placental Site Trophoblastic Tumor</li><li>\u2022 Epithelioid Trophoblastic Tumor</li><li>\u2022 Epithelioid Trophoblastic Tumor</li><li>\u2022 A partial mole is a type of hydatidiform mole and is considered benign. It is not included under GTN as it does not have malignant potential unless it transforms into an invasive mole, which is rare.</li><li>\u2022 partial mole</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Choriocarcinoma : This is a malignant form of GTD and is classified under GTN.</li><li>\u2022 Option B. Choriocarcinoma</li><li>\u2022 Option C. Placental Site Trophoblastic Tumor : This is another malignant form of GTD and is included under GTN.</li><li>\u2022 Option C. Placental Site Trophoblastic Tumor</li><li>\u2022 Option D. Invasive Mole : An invasive mole is a malignant transformation of a hydatidiform mole and is included under GTN.</li><li>\u2022 Option D. Invasive Mole</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Partial moles are not classified as gestational trophoblastic neoplasia (GTN) because they are generally benign and non-malignant.</li><li>\u27a4 Ref: Page no 615, Williams Obstetrics 26 th edition</li><li>\u27a4 Ref: Page no 615, Williams Obstetrics 26 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d984ebef",
      "audio": ""
    },
    {
      "text": "A pregnant woman presents with a genital lesion as shown below. What is the best treatment option for her? (FMGE JANUARY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Surgical excision",
          "correct": false
        },
        {
          "label": "B",
          "text": "Podophyllin",
          "correct": false
        },
        {
          "label": "C",
          "text": "5% imiquimod",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cryotherapy",
          "correct": true
        }
      ],
      "correct_answer": "D. Cryotherapy",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/07/screenshot-2024-06-07-125512.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Cryotherapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The image depicts a genital wart, which is caused by the human papillomavirus (HPV), specifically referred to as condyloma acuminata. In the context of pregnancy, the treatment options for genital warts must be chosen with caution to ensure the safety of both the mother and the fetus.</li><li>\u2022 Treatment Considerations in Pregnancy:</li><li>\u2022 Cryotherapy: This method involves freezing the wart with liquid nitrogen, which is a safe and effective treatment for genital warts during pregnancy. It is widely preferred due to its safety profile and effectiveness. Trichloroacetic acid is another safe option during pregnancy for treating genital warts.</li><li>\u2022 Cryotherapy: This method involves freezing the wart with liquid nitrogen, which is a safe and effective treatment for genital warts during pregnancy. It is widely preferred due to its safety profile and effectiveness.</li><li>\u2022 Trichloroacetic acid is another safe option during pregnancy for treating genital warts.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Surgical excision: Though safe, it is not the first-line treatment in most cases unless the warts are extensive.</li><li>\u2022 Option A. Surgical excision:</li><li>\u2022 Option B. Podophyllin: Not recommended during pregnancy due to safety concerns.</li><li>\u2022 Option B. Podophyllin:</li><li>\u2022 Option C. 5% imiquimod: Also avoided during pregnancy due to safety concerns.</li><li>\u2022 Option C. 5% imiquimod:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The best treatment option for genital warts in a pregnant woman is cryotherapy, as it is safe and effective during pregnancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ab5020b1",
      "audio": ""
    },
    {
      "text": "A pregnant woman has gestational diabetes mellitus (GDM) and her blood glucose levels are well controlled on insulin. What will be the appropriate gestational age for her delivery? (INICET MAY 2018)",
      "options": [
        {
          "label": "A",
          "text": "37 weeks",
          "correct": false
        },
        {
          "label": "B",
          "text": "39 weeks",
          "correct": true
        },
        {
          "label": "C",
          "text": "38 weeks",
          "correct": false
        },
        {
          "label": "D",
          "text": "40 weeks",
          "correct": false
        }
      ],
      "correct_answer": "B. 39 weeks",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 39 weeks</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The appropriate timing of delivery in a pregnant woman with gestational diabetes mellitus (GDM) whose blood glucose levels are well controlled on insulin is at or after 39 weeks of gestation. This recommendation is based on the following considerations:</li><li>\u2022 Lung Maturity: GDM pregnancies are associated with a delay in fetal lung maturity. Routine delivery before 39 weeks is generally not recommended to avoid respiratory complications in the newborn. Induction of Labor: If the patient with well-controlled GDM has not delivered spontaneously by 39 weeks, induction of labor should be scheduled at or after 39 weeks to minimize the risks associated with GDM and to ensure fetal maturity.</li><li>\u2022 Lung Maturity: GDM pregnancies are associated with a delay in fetal lung maturity. Routine delivery before 39 weeks is generally not recommended to avoid respiratory complications in the newborn.</li><li>\u2022 Lung Maturity:</li><li>\u2022 Induction of Labor: If the patient with well-controlled GDM has not delivered spontaneously by 39 weeks, induction of labor should be scheduled at or after 39 weeks to minimize the risks associated with GDM and to ensure fetal maturity.</li><li>\u2022 Induction of Labor:</li><li>\u2022 Other important points in GDM:</li><li>\u2022 Other important points in GDM:</li><li>\u2022 Avoid Past Dates: Delivery should not be delayed beyond the expected due date to prevent complications. Anticipate Shoulder Dystocia: There is an increased risk of shoulder dystocia in infants of mothers with GDM. Prophylactic Cesarean Section (LSCS): Considered if the estimated fetal weight is greater than 4.5 kg to avoid complications during vaginal delivery.</li><li>\u2022 Avoid Past Dates: Delivery should not be delayed beyond the expected due date to prevent complications.</li><li>\u2022 Avoid Past Dates:</li><li>\u2022 Anticipate Shoulder Dystocia: There is an increased risk of shoulder dystocia in infants of mothers with GDM.</li><li>\u2022 Anticipate Shoulder Dystocia:</li><li>\u2022 Prophylactic Cesarean Section (LSCS): Considered if the estimated fetal weight is greater than 4.5 kg to avoid complications during vaginal delivery.</li><li>\u2022 Prophylactic Cesarean Section (LSCS):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a pregnant woman with well-controlled gestational diabetes mellitus (GDM) on insulin, the appropriate gestational age for delivery is at or after 39 weeks to ensure fetal lung maturity and reduce the risk of complications.</li><li>\u27a4 Ref: https://nhm.gov.in/images/pdf/programmes/maternal-health/guidelines/National_Guidelines_for_Diagnosis_&_Management_of_Gestational_Diabetes_Mellitus.pdf</li><li>\u27a4 Ref:</li><li>\u27a4 https://nhm.gov.in/images/pdf/programmes/maternal-health/guidelines/National_Guidelines_for_Diagnosis_&_Management_of_Gestational_Diabetes_Mellitus.pdf</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "646a41cf",
      "audio": ""
    },
    {
      "text": "A teenage patient presented with a history of dysmenorrhea and chronic pelvic pain. On ultrasonography, a transverse vaginal septum was seen. Which of the following is she likely to have? (NEET PG 2021)",
      "options": [
        {
          "label": "A",
          "text": "Endometriosis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tubo-ovarian abscess",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dermoid cyst",
          "correct": false
        },
        {
          "label": "D",
          "text": "Theca lutein cyst",
          "correct": false
        }
      ],
      "correct_answer": "A. Endometriosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Endometriosis</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Transverse vaginal septum, a Mullerian anomaly, can cause obstruction to menstrual flow leading to hematocolpos, hematometra, and endometriosis, presenting with dysmenorrhea and chronic pelvic pain.</li><li>\u27a4 Ref: Page no 34, DC Dutta\u2019s Textbook of Gynecology 8 th edition</li><li>\u27a4 Ref: Page no 34, DC Dutta\u2019s Textbook of Gynecology 8 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d882e96e",
      "audio": ""
    },
    {
      "text": "The classification shown is for? (NEET PG 2024)",
      "options": [
        {
          "label": "A",
          "text": "Cervical cancer",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pelvic organ prolapse",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vulvar cancer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Uterine anomalies",
          "correct": false
        }
      ],
      "correct_answer": "B. Pelvic organ prolapse",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/12/screenshot-2024-09-12-121711.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0 B) Pelvic organ prolapse</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The POP-Q system is a specific and standardized classification method used to quantify and describe the extent of pelvic organ prolapse using detailed anatomical measurements. The hymen is the reference point for this classification.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a0eea58b",
      "audio": ""
    },
    {
      "text": "A 24-year-old nulligravida presents with uterine prolapse. There is no cystocele or rectocele. What is the treatment of choice? (FMGE JULY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Leforte colpocleisis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fothergill surgery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Shirodkar surgery",
          "correct": false
        },
        {
          "label": "D",
          "text": "Abdominal sling surgery",
          "correct": true
        }
      ],
      "correct_answer": "D. Abdominal sling surgery",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Abdominal sling surgery</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For a young nulligravida with uterine prolapse and no cystocele or rectocele, abdominal sling surgery (hysteropexy) is the treatment of choice to preserve fertility and provide effective prolapse correction.</li><li>\u27a4 abdominal sling surgery</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "85c8e0dd",
      "audio": ""
    },
    {
      "text": "A 24-year-old woman visits the infertility clinic with a complaint of recurrent abortions. Upon investigations, she is found to have a septate uterus. Which of the following corrective procedures has the best obstetric outcome? (NEET PG 2020)",
      "options": [
        {
          "label": "A",
          "text": "Jones metroplasty",
          "correct": false
        },
        {
          "label": "B",
          "text": "Strassmann metroplasty",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tompkins metroplasty",
          "correct": false
        },
        {
          "label": "D",
          "text": "Transcervical resection of septum",
          "correct": true
        }
      ],
      "correct_answer": "D. Transcervical resection of septum",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/7.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Transcervical resection of septum</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Transcervical hysteroscopic resection of the septum has the best obstetric outcome. The procedure involves the resection of the septum under hysteroscopic guidance. Hence, it doesn't scar the uterus and avoids the necessity of Cesarean sections for future pregnancies improving the obstetric outcomes.</li><li>\u2022 Transcervical hysteroscopic resection of the septum has the best obstetric outcome.</li><li>\u2022 The procedure involves the resection of the septum under hysteroscopic guidance. Hence, it doesn't scar the uterus and avoids the necessity of Cesarean sections for future pregnancies improving the obstetric outcomes.</li><li>\u2022 Other Options</li><li>\u2022 Other Options</li><li>\u2022 Metroplasty is a type of unification procedures in mullerian anomalies</li><li>\u2022 Option A. Jones metroplasty and Option C. Tompkins metroplasty are for septate uterus but are not preferred now. As now the treatment of choice is hysteroscopic resection of the septa.</li><li>\u2022 Option A. Jones metroplasty</li><li>\u2022 Option C. Tompkins metroplasty</li><li>\u2022 Option B. Strassman metroplasty : Strassman metroplasty is for bicornuate uterus.</li><li>\u2022 Option B. Strassman metroplasty</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Transcervical hysteroscopic resection of the septum is the best corrective procedure for a septate uterus to improve obstetric outcomes, as it does not scar the uterus and allows for future vaginal deliveries.</li><li>\u27a4 Ref: Page no 659, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li><li>\u27a4 Ref: Page no 659, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a8fdec7c",
      "audio": ""
    },
    {
      "text": "A young girl presents with retention of urine and cyclical abdominal pain. On examination, there is a tense bluish bulge seen at the introitus. The diagnosis is? (INICET MAY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Imperforate hymen",
          "correct": true
        },
        {
          "label": "B",
          "text": "Transverse vaginal septum",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vertical vaginal septum",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mullerian agenesis",
          "correct": false
        }
      ],
      "correct_answer": "A. Imperforate hymen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Imperforate hymen</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The presence of cyclical abdominal pain, urinary retention, and a tense bluish bulge at the introitus in a young girl strongly suggests an imperforate hymen. Early diagnosis and surgical intervention can prevent complications and relieve symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "377bc685",
      "audio": ""
    },
    {
      "text": "A patient presents at 18 weeks with low risk of trisomy on quadruple marker and high risk of NTD. What is the next best step? (INICET MAY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Anomaly scan",
          "correct": true
        },
        {
          "label": "B",
          "text": "Amniocentesis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chorionic villous sampling",
          "correct": false
        },
        {
          "label": "D",
          "text": "NIPT",
          "correct": false
        }
      ],
      "correct_answer": "A. Anomaly scan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Anomaly scan</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a patient with a high risk of neural tube defects identified by elevated alpha-fetoprotein on a quadruple marker test, the best next step is an anomaly scan (TIFA), which is highly effective in identifying structural fetal abnormalities, including NTDs</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8c2f8c2f",
      "audio": ""
    },
    {
      "text": "A 16-year-old girl is seen for primary amenorrhea. She has not development of breasts or hair in the pubic or axillary region. Her height is 155cm and her weight is 48 kg. She has bilateral inguinal masses. On USG examination, the uterus, fallopian tube, and ovary are absent. What is the most likely diagnosis? (NEET PG 2023)",
      "options": [
        {
          "label": "A",
          "text": "Complete androgen insensitivity syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypergonadotropic hypogonadism",
          "correct": true
        },
        {
          "label": "C",
          "text": "Turner syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Polycystic ovary syndrome",
          "correct": false
        }
      ],
      "correct_answer": "B. Hypergonadotropic hypogonadism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hypergonadotropic hypogonadism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The diagnosis based on the given clinical scenario is hypergonadotropic hypogonadism. In this question, bilateral inguinal masses (undescended testis), absent ovary, also there is absent uterus and fallopian tubes, all pointing to a conclusion that patient can be of XY karyotype. Because if female reproductive tract is absent, there must be mullerian inhibiting substance present which comes from Y chromosome. Hypergonadotropic hypogonadism can occur in disorders such as FSH or LH receptor mutations. Now, in a XY individual with a defect in LH/hCG receptor, testis\u2019 Sertoli cells will produce Anti-mullerian hormone which will not let uterus, fallopian tube, cervix, upper vagina to develop. Leydi cells will not produce testosterone due to which wolffian duct development is impaired and the testes fail to descend. They appear female at birth and at puberty present with primary amenorrhea. They lack breast development and pubic hair development.</li><li>\u2022 The diagnosis based on the given clinical scenario is hypergonadotropic hypogonadism.</li><li>\u2022 In this question, bilateral inguinal masses (undescended testis), absent ovary, also there is absent uterus and fallopian tubes, all pointing to a conclusion that patient can be of XY karyotype. Because if female reproductive tract is absent, there must be mullerian inhibiting substance present which comes from Y chromosome.</li><li>\u2022 Hypergonadotropic hypogonadism can occur in disorders such as FSH or LH receptor mutations.</li><li>\u2022 Now, in a XY individual with a defect in LH/hCG receptor, testis\u2019 Sertoli cells will produce Anti-mullerian hormone which will not let uterus, fallopian tube, cervix, upper vagina to develop. Leydi cells will not produce testosterone due to which wolffian duct development is impaired and the testes fail to descend. They appear female at birth and at puberty present with primary amenorrhea. They lack breast development and pubic hair development.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Complete androgen insensitivity syndrome : Androgen insensitivity syndrome individuals have normal breast development.</li><li>\u2022 Option A. Complete androgen insensitivity syndrome</li><li>\u2022 Option C. Turner syndrome : Turner's syndrome karyotype is XO.</li><li>\u2022 Option C. Turner syndrome</li><li>\u2022 Option D. Polycystic ovary syndrome : In Polycystic ovarian syndrome (PCOS) ovary and uterus is present, so can\u2019t be answer.</li><li>\u2022 Option D. Polycystic ovary syndrome</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hypergonadotropic hypogonadism can present as primary amenorrhea with absent uterus, fallopian tubes, and ovaries in an XY individual, with bilateral inguinal masses indicating undescended testes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e39bb35a",
      "audio": ""
    },
    {
      "text": "Which of the following is not a long-acting reversible contraceptive method? (INICET MAY 2021)",
      "options": [
        {
          "label": "A",
          "text": "Copper T",
          "correct": false
        },
        {
          "label": "B",
          "text": "Implanon",
          "correct": false
        },
        {
          "label": "C",
          "text": "Laparoscopic tubal ligation",
          "correct": true
        },
        {
          "label": "D",
          "text": "SC DMPA",
          "correct": false
        }
      ],
      "correct_answer": "C. Laparoscopic tubal ligation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Laparoscopic tubal ligation</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Laparoscopic tubal ligation is a permanent method of contraception and is not a long-acting reversible contraceptive (LARC).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c877d4c7",
      "audio": ""
    },
    {
      "text": "G2 at 8 weeks diagnosed to have hyperthyroidism. What is the drug of choice? (NEET PG 2024)",
      "options": [
        {
          "label": "A",
          "text": "Methimazole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carbimazole",
          "correct": false
        },
        {
          "label": "C",
          "text": "Iodine 131",
          "correct": false
        },
        {
          "label": "D",
          "text": "Propylthiouracil",
          "correct": true
        }
      ],
      "correct_answer": "D. Propylthiouracil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Propylthiouracil</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the first trimester of pregnancy, propylthiouracil (PTU) is the drug of choice for hyperthyroidism due to its safer profile compared to other antithyroid medications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "293fce39",
      "audio": ""
    },
    {
      "text": "Which of the following is not a cause of secondary PPH? (NEET PG 2018)",
      "options": [
        {
          "label": "A",
          "text": "Retained cotyledon",
          "correct": false
        },
        {
          "label": "B",
          "text": "Endometritis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Placental polyp",
          "correct": false
        },
        {
          "label": "D",
          "text": "Placenta previa",
          "correct": true
        }
      ],
      "correct_answer": "D. Placenta previa",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Placenta previa</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Placenta previa is not a cause of secondary postpartum hemorrhage (PPH). It is primarily associated with antepartum hemorrhage (bleeding before delivery) and is a risk factor for primary PPH (occurring within the first 24 hours after childbirth).</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Retained cotyledon : Retained cotyledon can lead to secondary PPH due to retained placental fragments, causing continued uterine bleeding.</li><li>\u2022 Option A. Retained cotyledon</li><li>\u2022 Option B. Endometritis : Endometritis, an infection of the uterine lining, can cause secondary PPH by leading to inflammation and impaired uterine contraction.</li><li>\u2022 Option B. Endometritis</li><li>\u2022 Option C. Placental polyp : A placental polyp, which is retained placental tissue that forms a growth, can cause secondary PPH through persistent bleeding.</li><li>\u2022 Option C. Placental polyp</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Placenta previa is a cause of antepartum hemorrhage and primary postpartum hemorrhage but not secondary postpartum hemorrhage.</li><li>\u27a4 Ref: Page no 804, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li><li>\u27a4 Ref: Page no 804, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "08a59763",
      "audio": ""
    },
    {
      "text": "All of the subsequent factors can lead to non-immune hydrops except for: (INICET MAY 2023)",
      "options": [
        {
          "label": "A",
          "text": "ABO incompatibility",
          "correct": true
        },
        {
          "label": "B",
          "text": "Parvovirus B19",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chromosomal defect",
          "correct": false
        },
        {
          "label": "D",
          "text": "Alpha thalassemia major",
          "correct": false
        }
      ],
      "correct_answer": "A. ABO incompatibility",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/05/screenshot-2024-08-05-105104.png"
      ],
      "explanation": "<p><strong>Ans. A) ABO incompatibility</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Non-immune hydrops refers to fetal hydrops that occur due to causes other than those related to maternal-fetal blood group incompatibility. ABO incompatibility is an immune-related cause of hydrops, known as immune hydrops, where the mother's immune system attacks the fetus's red blood cells due to incompatible ABO blood types. Non-immune hydrops arises from various other causes such as cardiovascular issues, genetic disorders, congenital infections, hematologic disorders, placental problems, and miscellaneous conditions.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option B. Parvovirus B19 : This is a viral infection that can cause non-immune hydrops by affecting the fetus's red blood cells, leading to severe anemia and hydrops.</li><li>\u2022 Option B. Parvovirus B19</li><li>\u2022 Option C. Chromosomal defect : Chromosomal abnormalities, such as trisomy 21, 18, or 13, can cause non-immune hydrops through associated congenital abnormalities or malformations.</li><li>\u2022 Option C. Chromosomal defect</li><li>\u2022 Option D. Alpha thalassemia major : This is a hematologic disorder that results in severe anemia, which can lead to non-immune hydrops.</li><li>\u2022 Option D. Alpha thalassemia major</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 ABO incompatibility leads to immune hydrops and is not a cause of non-immune hydrops.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f5964413",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman has cervical intraepithelial neoplasia III. What would be the management? (INICET MAY 2018)",
      "options": [
        {
          "label": "A",
          "text": "Hysterectomy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Trachelectomy",
          "correct": false
        },
        {
          "label": "C",
          "text": "Conization",
          "correct": false
        },
        {
          "label": "D",
          "text": "Colposcopy with LEEP",
          "correct": true
        }
      ],
      "correct_answer": "D. Colposcopy with LEEP",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Colposcopy with LEEP</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Cervical intraepithelial neoplasia III (CIN 3) is a severe form of cervical dysplasia that is diagnosed by cervical biopsy. The standard treatment for CIN 2 or CIN 3 is an excisional procedure, which aims to remove the affected tissue to prevent progression to invasive cancer.</li><li>\u2022 LEEP (Loop Electrosurgical Excision Procedure): LEEP is the excisional procedure of choice for treating CIN 3. It involves using a thin wire loop that is heated by electric current to excise the transformation zone of the cervix where abnormal cells are located. LEEP is also known as LLETZ (Large Loop Excision of the Transformation Zone).</li><li>\u2022 LEEP (Loop Electrosurgical Excision Procedure):</li><li>\u2022 LEEP (Loop Electrosurgical Excision Procedure):</li><li>\u2022 LEEP is the excisional procedure of choice for treating CIN 3. It involves using a thin wire loop that is heated by electric current to excise the transformation zone of the cervix where abnormal cells are located. LEEP is also known as LLETZ (Large Loop Excision of the Transformation Zone).</li><li>\u2022 LEEP is the excisional procedure of choice for treating CIN 3. It involves using a thin wire loop that is heated by electric current to excise the transformation zone of the cervix where abnormal cells are located. LEEP is also known as LLETZ (Large Loop Excision of the Transformation Zone).</li><li>\u2022 LEEP is the excisional procedure of choice for treating CIN 3.</li><li>\u2022 It involves using a thin wire loop that is heated by electric current to excise the transformation zone of the cervix where abnormal cells are located.</li><li>\u2022 LEEP is also known as LLETZ (Large Loop Excision of the Transformation Zone).</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Hysterectomy: This is a more radical procedure that involves the removal of the uterus. It is generally not the first-line treatment for CIN 3 unless there are other indications, such as concurrent invasive cancer or other gynecological conditions.</li><li>\u2022 Option A. Hysterectomy:</li><li>\u2022 Option B. Trachelectomy: This procedure involves removing the cervix while preserving the uterus. It is more commonly used for early-stage cervical cancer in women who wish to preserve fertility.</li><li>\u2022 Option B. Trachelectomy:</li><li>\u2022 Option C. Conization: While conization (removal of a cone-shaped piece of tissue from the cervix) is a valid treatment for CIN 3, LEEP is often preferred due to its effectiveness and lower morbidity.</li><li>\u2022 Option C. Conization:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CIN 3 is best treated with an excisional procedure, with the Loop Electrosurgical Excision Procedure (LEEP) being the procedure of choice.</li><li>\u27a4 Ref: Page no 328, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li><li>\u27a4 Ref: Page no 328, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "af54b090",
      "audio": ""
    },
    {
      "text": "Which class of ovarian tumor does clear cell carcinoma of the ovary belong to? (INICET MAY 2021)",
      "options": [
        {
          "label": "A",
          "text": "Epithelial cell tumor",
          "correct": true
        },
        {
          "label": "B",
          "text": "Germ cell tumor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sex cord stromal tumor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Granulosa cell tumor",
          "correct": false
        }
      ],
      "correct_answer": "A. Epithelial cell tumor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Epithelial cell tumor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Clear cell carcinoma of the ovary is classified under epithelial cell tumors. Epithelial ovarian tumors originate from the cells that line the surface of the ovary. Clear cell carcinoma is a subtype of epithelial ovarian tumors.</li><li>\u2022 Clear cell carcinoma of the ovary</li><li>\u2022 Classification of ovarian tumors:</li><li>\u2022 Classification of ovarian tumors:</li><li>\u2022 Epithelial Cell Tumor Serous Mucinous Brenner Clear cell Endometrioid Clear cell carcinoma falls under this category. Germ Cell Tumor Dysgerminoma Yolk sac tumor Choriocarcinoma Teratoma Embryonal Clear cell carcinoma is not classified here. Sex Cord Stromal Tumor Granulosa cell tumor Thecoma Fibroma Sertoli-Leydig cell tumor Clear cell carcinoma is not included in this category.</li><li>\u2022 Epithelial Cell Tumor Serous Mucinous Brenner Clear cell Endometrioid Clear cell carcinoma falls under this category.</li><li>\u2022 Epithelial Cell Tumor</li><li>\u2022 Serous Mucinous Brenner Clear cell Endometrioid Clear cell carcinoma falls under this category.</li><li>\u2022 Serous</li><li>\u2022 Serous</li><li>\u2022 Mucinous</li><li>\u2022 Mucinous</li><li>\u2022 Brenner</li><li>\u2022 Brenner</li><li>\u2022 Clear cell</li><li>\u2022 Clear cell</li><li>\u2022 Endometrioid</li><li>\u2022 Endometrioid</li><li>\u2022 Clear cell carcinoma falls under this category.</li><li>\u2022 Clear cell carcinoma</li><li>\u2022 Germ Cell Tumor Dysgerminoma Yolk sac tumor Choriocarcinoma Teratoma Embryonal Clear cell carcinoma is not classified here.</li><li>\u2022 Germ Cell Tumor</li><li>\u2022 Dysgerminoma Yolk sac tumor Choriocarcinoma Teratoma Embryonal Clear cell carcinoma is not classified here.</li><li>\u2022 Dysgerminoma</li><li>\u2022 Dysgerminoma</li><li>\u2022 Yolk sac tumor</li><li>\u2022 Yolk sac tumor</li><li>\u2022 Choriocarcinoma</li><li>\u2022 Choriocarcinoma</li><li>\u2022 Teratoma</li><li>\u2022 Teratoma</li><li>\u2022 Embryonal</li><li>\u2022 Embryonal</li><li>\u2022 Clear cell carcinoma is not classified here.</li><li>\u2022 Clear cell carcinoma</li><li>\u2022 Sex Cord Stromal Tumor Granulosa cell tumor Thecoma Fibroma Sertoli-Leydig cell tumor Clear cell carcinoma is not included in this category.</li><li>\u2022 Sex Cord Stromal Tumor</li><li>\u2022 Granulosa cell tumor Thecoma Fibroma Sertoli-Leydig cell tumor Clear cell carcinoma is not included in this category.</li><li>\u2022 Granulosa cell tumor</li><li>\u2022 Granulosa cell tumor</li><li>\u2022 Thecoma</li><li>\u2022 Thecoma</li><li>\u2022 Fibroma</li><li>\u2022 Fibroma</li><li>\u2022 Sertoli-Leydig cell tumor</li><li>\u2022 Sertoli-Leydig cell tumor</li><li>\u2022 Clear cell carcinoma is not included in this category.</li><li>\u2022 Clear cell carcinoma</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Clear cell carcinoma of the ovary is classified as an epithelial cell tumor.</li><li>\u27a4 Ref: Page no 291, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li><li>\u27a4 Ref: Page no 291, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d552e1e",
      "audio": ""
    },
    {
      "text": "A 33-year-old female patient comes with complaints of menorrhagia for the past 3 months. The duration and regularity of her menstrual cycles are normal. Non- hormonal management has been tried without success. What is the most appropriate next step? (NEET PG 2020)",
      "options": [
        {
          "label": "A",
          "text": "Uterine artery embolization",
          "correct": false
        },
        {
          "label": "B",
          "text": "Endometrial ablation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hormonal therapy",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hysterectomy",
          "correct": false
        }
      ],
      "correct_answer": "C. Hormonal therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Hormonal therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hormonal therapy is the next best management modality for menorrhagia when non-hormonal management has failed. This includes combined oral contraceptive pills or even progesterone-only devices like the LND-IUS. First-line management includes non-hormonal treatment like NSAIDs and Tranexamic acid.</li><li>\u2022 Hormonal therapy is the next best management modality for menorrhagia when non-hormonal management has failed. This includes combined oral contraceptive pills or even progesterone-only devices like the LND-IUS.</li><li>\u2022 First-line management includes non-hormonal treatment like NSAIDs and Tranexamic acid.</li><li>\u2022 Other Options</li><li>\u2022 Other Options</li><li>\u2022 Option A. Uterine artery embolization : Uterine artery embolization is a surgical option and is considered when other treatments fail.</li><li>\u2022 Option A. Uterine artery embolization</li><li>\u2022 Option B. Endometrial ablation : Endometrial ablation is also a surgical option and should be considered after hormonal therapy.</li><li>\u2022 Option B. Endometrial ablation</li><li>\u2022 Option D. Hysterectomy : Hysterectomy is the last resort and is used when all other management options fail or are contraindicated.</li><li>\u2022 Option D. Hysterectomy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Hormonal therapy, including combined oral contraceptive pills or progesterone-only devices like the LND-IUS, is the next best management step for menorrhagia when non-hormonal management has been ineffective.</li><li>\u27a4 Ref: Page no 197, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li><li>\u27a4 Ref: Page no 197, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c92a54f6",
      "audio": ""
    },
    {
      "text": "Identify the procedure done in the labor room? (INICET NOV 2018)",
      "options": [
        {
          "label": "A",
          "text": "Amniocentesis",
          "correct": false
        },
        {
          "label": "B",
          "text": "\ufeff\ufeff\ufeffMCA doppler",
          "correct": false
        },
        {
          "label": "C",
          "text": "\ufeff\ufeff\ufeffCardiotocography",
          "correct": true
        },
        {
          "label": "D",
          "text": "\ufeff\ufeff\ufeffAmniotic fluid index determination",
          "correct": false
        }
      ],
      "correct_answer": "C. \ufeff\ufeff\ufeffCardiotocography",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_ttNZkYp.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cardiotocography</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The image shows a procedure called Cardiotocography (CTG). CTG is a method used to monitor the fetal heart rate (FHR) and uterine contractions during pregnancy and labor. It helps assess the well-being of the fetus and identify any signs of fetal distress.</li><li>\u2022 Key points about Cardiotocography (CTG):</li><li>\u2022 Key points about Cardiotocography (CTG):</li><li>\u2022 If done antenatally (when the patient is not in labor), it is called a Non-Stress Test (NST). During labor, CTG is used to continuously monitor the fetal heart rate and contractions to ensure the fetus is not in distress.</li><li>\u2022 If done antenatally (when the patient is not in labor), it is called a Non-Stress Test (NST).</li><li>\u2022 If done antenatally (when the patient is not in labor), it is called a Non-Stress Test (NST).</li><li>\u2022 During labor, CTG is used to continuously monitor the fetal heart rate and contractions to ensure the fetus is not in distress.</li><li>\u2022 During labor, CTG is used to continuously monitor the fetal heart rate and contractions to ensure the fetus is not in distress.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Amniocentesis: Amniocentesis is an invasive procedure in which a sample of amniotic fluid is aspirated for prenatal diagnosis or therapeutic purposes. This is not the procedure shown in the image.</li><li>\u2022 Option A. Amniocentesis:</li><li>\u2022 Option B. MCA Doppler: MCA (Middle Cerebral Artery) Doppler is performed to assess fetal growth restriction and fetal anemia. It is an ultrasound procedure and does not match the image shown.</li><li>\u2022 Option B. MCA Doppler:</li><li>\u2022 Option D. Amniotic Fluid Index (AFI): AFI is an ultrasound estimation of amniotic fluid volume. It is not depicted in the image.</li><li>\u2022 Option D. Amniotic Fluid Index (AFI):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Cardiotocography (CTG) is used to monitor the fetal heart rate and uterine contractions during pregnancy and labor. When performed antenatally without labor, it is referred to as a Non-Stress Test (NST).</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 24 th edition pg339, Dutta\u2019s textbook of obstetrics 8 th edition pg122</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 24 th edition pg339, Dutta\u2019s textbook of obstetrics 8 th edition pg122</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a307d179",
      "audio": ""
    },
    {
      "text": "Asherman syndrome is most commonly associated with? (INICET MAY 2021)",
      "options": [
        {
          "label": "A",
          "text": "Oligomenorrhea",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypomenorrhea",
          "correct": true
        },
        {
          "label": "C",
          "text": "Dysmenorrhea",
          "correct": false
        },
        {
          "label": "D",
          "text": "Menorrhagia",
          "correct": false
        }
      ],
      "correct_answer": "B. Hypomenorrhea",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/05/screenshot-2024-08-05-171526.png"
      ],
      "explanation": "<p><strong>Ans. B) Hypomenorrhea</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Asherman syndrome is most commonly associated with hypomenorrhea due to intrauterine adhesions following endometrial trauma.</li><li>\u27a4 Ref: Page no 459, DC Dutta\u2019s Textbook of gynecology 6 th edition</li><li>\u27a4 Ref: Page no 459, DC Dutta\u2019s Textbook of gynecology 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "703cebff",
      "audio": ""
    },
    {
      "text": "Which of these statements regarding primary dysmenorrhea is true? (INICET MAY 2023)",
      "options": [
        {
          "label": "A",
          "text": "Pain begins after few hours of onset of periods and can last up to 48 hours",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is dependent on psychological factors",
          "correct": true
        },
        {
          "label": "C",
          "text": "Pain begins 3 days prior to the onset of periods and is present up to the second day of the period",
          "correct": false
        },
        {
          "label": "D",
          "text": "GnRH antagonists are the first line of treatment",
          "correct": false
        }
      ],
      "correct_answer": "B. It is dependent on psychological factors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It Is dependent on psychological factors</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Primary dysmenorrhea, characterized by menstrual pain without underlying pelvic pathology, can be influenced by psychological factors. This type of dysmenorrhea begins before or with the onset of menstrual periods and is typically treated first with NSAIDs, not GnRH antagonists.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "18d162f7",
      "audio": ""
    },
    {
      "text": "A pregnant woman presents for a routine antenatal checkup at 18 weeks of gestation. On abdominal examination, the uterine size was found to correspond to 16 weeks of gestation. On US, oligohydramnios was found. Which of the following is a likely cause? (NEET PG 2020)",
      "options": [
        {
          "label": "A",
          "text": "Renal agenesis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Fetal anemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Barter syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anencephaly",
          "correct": false
        }
      ],
      "correct_answer": "A. Renal agenesis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Renal agenesis</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Early onset oligohydramnios can be due to renal anomalies like bilateral renal agenesis, bilateral dysplastic kidneys, or bilateral autosomal recessive infantile polycystic kidney disease.</li><li>\u27a4 Ref: Page no 352, Williams Obstetrics 26 th edition</li><li>\u27a4 Ref: Page no 352, Williams Obstetrics 26 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a4d5368e",
      "audio": ""
    },
    {
      "text": "Which is NOT a hyper-estrogenic condition? (FMGE JULY 2023)",
      "options": [
        {
          "label": "A",
          "text": "Low BMI",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tamoxifen use",
          "correct": false
        },
        {
          "label": "C",
          "text": "Nulliparous",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ovarian cancer",
          "correct": false
        }
      ],
      "correct_answer": "A. Low BMI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Low BMI</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hyper-estrogenic conditions are characterized by elevated levels of estrogen. Such conditions can arise due to various factors, including hormonal imbalances, medications, and specific medical conditions.</li><li>\u2022 Low BMI : This is not typically associated with high estrogen levels. In fact, individuals with low BMI may have lower estrogen levels due to decreased adipose tissue, which is a source of estrogen production.</li><li>\u2022 Low BMI</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Tamoxifen use : Tamoxifen is a selective estrogen receptor modulator (SERM) used primarily in the treatment of breast cancer. It can act as an estrogen agonist in certain tissues, potentially leading to increased estrogenic effects.</li><li>\u2022 Option B. Tamoxifen use</li><li>\u2022 Option C. Nulliparous : Nulliparous women (those who have never given birth) may have higher lifetime exposure to estrogen due to the absence of pregnancy and lactation periods, which would otherwise lower estrogen exposure.</li><li>\u2022 Option C. Nulliparous</li><li>\u2022 Option D. Ovarian cancer : Certain types of ovarian cancer can lead to increased estrogen production, contributing to a hyper-estrogenic state.</li><li>\u2022 Option D. Ovarian cancer</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Low BMI is not associated with hyper-estrogenic conditions.</li><li>\u27a4 High estrogen levels are more likely to be seen in conditions such as Tamoxifen use, nulliparity, and certain types of ovarian cancer.</li><li>\u27a4 High estrogen is a risk factors for fibroids, endometrial hyperplasia, endometrial carcinoma and endometriosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "39e6ed28",
      "audio": ""
    },
    {
      "text": "A primigravida presents to the labor room at 40 weeks of gestation with lower abdominal pain. She has been in labor for 3 hours. Which of the following will determine if she is in active labor? (NEET PG 2022)",
      "options": [
        {
          "label": "A",
          "text": "Fetal head 5/5 palpable on abdominal examination",
          "correct": false
        },
        {
          "label": "B",
          "text": "Two contractions lasting for 10 seconds in 10 minutes",
          "correct": false
        },
        {
          "label": "C",
          "text": "More than 5 cm cervical dilatation with complete effacement",
          "correct": true
        },
        {
          "label": "D",
          "text": "Rupture of membranes",
          "correct": false
        }
      ],
      "correct_answer": "C. More than 5 cm cervical dilatation with complete effacement",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) More than 5 cm cervical dilatation with complete effacement</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Active labor is determined by more than 5 cm of cervical dilatation with complete effacement, according to the WHO Labor Care Guide.</li><li>\u27a4 Ref: Page no 138, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li><li>\u27a4 Ref: Page no 138, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e2354f7d",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman in her second pregnancy is diagnosed with deep vein thrombosis (DVT) at 30 weeks gestation. What is the drug of choice for her treatment? (NEET PG 2024)",
      "options": [
        {
          "label": "A",
          "text": "Warfarin",
          "correct": false
        },
        {
          "label": "B",
          "text": "LMWH (Low Molecular Weight Heparin)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Fondaparinux",
          "correct": false
        },
        {
          "label": "D",
          "text": "Apixaban",
          "correct": false
        }
      ],
      "correct_answer": "B. LMWH (Low Molecular Weight Heparin)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) LMWH (Low Molecular Weight Heparin)</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In pregnancy, the drug of choice for treating DVT is Low Molecular Weight Heparin (LMWH) due to its safety and ease of monitoring compared to other anticoagulants</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6f427ee3",
      "audio": ""
    },
    {
      "text": "A G2P1L1 with a previous cesarean section now presents at term. Which of the following is most favorable for a vaginal birth? (FMGE JANUARY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Previous upper segment cesarean",
          "correct": false
        },
        {
          "label": "B",
          "text": "Previous lower segment cesarean",
          "correct": true
        },
        {
          "label": "C",
          "text": "Previous J-shaped cesarean",
          "correct": false
        },
        {
          "label": "D",
          "text": "Previous T-shaped cesarean",
          "correct": false
        }
      ],
      "correct_answer": "B. Previous lower segment cesarean",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Previous lower segment cesarean</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The type of uterine incision from a previous cesarean section significantly impacts the safety and likelihood of a successful vaginal birth after caesarean (VBAC).</li><li>\u2022 The lower segment cesarean section (LSCS) involves a transverse incision made in the lower, thinner part of the uterus. This type of incision is most favorable for a vaginal birth due to its lower risk of uterine rupture during labor, which is around 0.2%.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Other Incision Types and Associated Risks:</li><li>\u2022 Option A. Previous upper segment cesarean: This is also known as a classical cesarean section, where the incision is made vertically in the thicker, upper part of the uterus. The risk of uterine rupture with this type of incision is significantly higher, ranging from 4-9%.</li><li>\u2022 Option A. Previous upper segment cesarean:</li><li>\u2022 Option C. Previous J-shaped cesarean: This incision extends from the lower segment into the upper segment, increasing the risk of rupture to 4-9%.</li><li>\u2022 Option C. Previous J-shaped cesarean:</li><li>\u2022 Option D. Previous T-shaped cesarean: This incision combines a lower segment transverse incision with a vertical extension into the upper segment, also associated with a 4-9% risk of rupture.</li><li>\u2022 Option D. Previous T-shaped cesarean:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The most favorable incision for a vaginal birth after a previous cesarean section is the lower segment transverse incision due to its lower risk of uterine rupture during labor.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "344edafe",
      "audio": ""
    },
    {
      "text": "Modified biophysical profile includes? (INICET MAY 2022)",
      "options": [
        {
          "label": "A",
          "text": "NST and fetal tone",
          "correct": false
        },
        {
          "label": "B",
          "text": "NST and AFI",
          "correct": true
        },
        {
          "label": "C",
          "text": "NST and breathing movements",
          "correct": false
        },
        {
          "label": "D",
          "text": "NST and gross fetal movements",
          "correct": false
        }
      ],
      "correct_answer": "B. NST and AFI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) NST and AFI</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Modified Biophysical Profile (BPP) includes the Non-Stress Test (NST) and the Amniotic Fluid Index (AFI).</li><li>\u27a4 Ref: Page no 980, Williams Obstetrics 26 th edition</li><li>\u27a4 Ref: Page no 980, Williams Obstetrics 26 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "50dcf10c",
      "audio": ""
    },
    {
      "text": "A woman presents with prolonged labor in emergency. She is being taken for a Cesarean section. Which of the following is the correct position in which the nurse should keep the patient on the OT table? (INICET NOV 2018)",
      "options": [
        {
          "label": "A",
          "text": "Supine with wedge under right hip",
          "correct": true
        },
        {
          "label": "B",
          "text": "Semi fowlers",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trendelenburg with legs stirrup",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prone position",
          "correct": false
        }
      ],
      "correct_answer": "A. Supine with wedge under right hip",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Supine with wedge under right hip</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The preferred position for a cesarean section is supine with a wedge under the right hip. This positioning is crucial to prevent supine hypotension syndrome, which is commonly seen in the third trimester of pregnancy.</li><li>\u2022 Supine hypotension syndrome:</li><li>\u2022 Supine hypotension syndrome:</li><li>\u2022 Occurs due to the pressure of the gravid uterus on the inferior vena cava (IVC) when the patient is in the supine position. This pressure can cause hypotension, tachycardia, and syncope. It is particularly dangerous during cesarean sections where spinal anesthesia can exacerbate hypotension. A right tilt (placing a wedge under the right hip) helps to alleviate the pressure on the IVC, thereby preventing hypotension.</li><li>\u2022 Occurs due to the pressure of the gravid uterus on the inferior vena cava (IVC) when the patient is in the supine position.</li><li>\u2022 This pressure can cause hypotension, tachycardia, and syncope.</li><li>\u2022 It is particularly dangerous during cesarean sections where spinal anesthesia can exacerbate hypotension.</li><li>\u2022 A right tilt (placing a wedge under the right hip) helps to alleviate the pressure on the IVC, thereby preventing hypotension.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option B. Semi fowlers: The individual lies on the bed with the head elevated 30-45 degrees. This position is not suitable for a cesarean section.</li><li>\u2022 Option B. Semi fowlers:</li><li>\u2022 Option C. Trendelenburg with legs stirrup: This position involves having the head low and is not appropriate for a cesarean section. The reverse Trendelenburg position (head high) is also not suitable for this purpose.</li><li>\u2022 Option C. Trendelenburg with legs stirrup:</li><li>\u2022 Option D. Prone position: The prone position (lying face down) is inappropriate for cesarean sections.</li><li>\u2022 Option D. Prone position:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 During a cesarean section, the patient should be positioned supine with a wedge under the right hip to prevent supine hypotension syndrome, which is caused by the pressure of the gravid uterus on the inferior vena cava.</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 26 th edition pg 1405</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 26 th edition pg 1405</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f18e8163",
      "audio": ""
    },
    {
      "text": "What is the true statement regarding level of uterus just after delivery? (FMGE JANUARY 2023)",
      "options": [
        {
          "label": "A",
          "text": "Below pubic symphysis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Above pubic symphysis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Below umbilicus",
          "correct": true
        },
        {
          "label": "D",
          "text": "Above umbilicus",
          "correct": false
        }
      ],
      "correct_answer": "C. Below umbilicus",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/12/screenshot-2024-08-12-112353.png"
      ],
      "explanation": "<p><strong>Ans. C) Below umbilicus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Below pubic symphysis: This is not accurate immediately after delivery as the uterus is still quite large and palpable above the pubic symphysis.</li><li>\u2022 Option A. Below pubic symphysis:</li><li>\u2022 Option B. Above pubic symphysis: While this is true in a general sense postpartum, it is not specific enough to accurately describe the position immediately after delivery.</li><li>\u2022 Option B. Above pubic symphysis:</li><li>\u2022 Option D. Above umbilicus: This is incorrect because the uterus immediately after delivery is positioned at the lower border of the umbilicus, not above it.</li><li>\u2022 Option D. Above umbilicus:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Immediately after delivery, the uterus is positioned at the lower border of the umbilicus, equivalent to the size it would be at 20 weeks of gestation.</li><li>\u27a4 Ref: D. C. Dutta\u2019s Textbook of Obstetrics 8 th Edition page 170</li><li>\u27a4 Ref: D. C. Dutta\u2019s Textbook of Obstetrics 8 th Edition page 170</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b8367f37",
      "audio": ""
    },
    {
      "text": "Which of the following is the best measures ovarian reserve? (INICET NOV 2021)",
      "options": [
        {
          "label": "A",
          "text": "Luteal phase LH",
          "correct": false
        },
        {
          "label": "B",
          "text": "Post luteal phase LH",
          "correct": false
        },
        {
          "label": "C",
          "text": "FSH in the follicular phase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti-Mullerian hormone (AMH)",
          "correct": true
        }
      ],
      "correct_answer": "D. Anti-Mullerian hormone (AMH)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Anti-Mullerian hormone (AMH)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Anti-Mullerian Hormone (AMH) is a glycoprotein secreted by the granulosa cells of pre-antral follicles. It is the best marker of ovarian reserve because it can be tested on any day of the cycle. Values and Interpretation: Normal value: 2-6.8 ng/mL Poor ovarian reserve: <1 ng/mL Polycystic Ovary Disease (PCOD) and Hyperstimulation Syndrome: >10 ng/mL</li><li>\u2022 Anti-Mullerian Hormone (AMH) is a glycoprotein secreted by the granulosa cells of pre-antral follicles. It is the best marker of ovarian reserve because it can be tested on any day of the cycle.</li><li>\u2022 Anti-Mullerian Hormone (AMH)</li><li>\u2022 Values and Interpretation: Normal value: 2-6.8 ng/mL Poor ovarian reserve: <1 ng/mL Polycystic Ovary Disease (PCOD) and Hyperstimulation Syndrome: >10 ng/mL</li><li>\u2022 Values and Interpretation:</li><li>\u2022 Normal value: 2-6.8 ng/mL Poor ovarian reserve: <1 ng/mL Polycystic Ovary Disease (PCOD) and Hyperstimulation Syndrome: >10 ng/mL</li><li>\u2022 Normal value: 2-6.8 ng/mL</li><li>\u2022 Normal value:</li><li>\u2022 Poor ovarian reserve: <1 ng/mL</li><li>\u2022 Poor ovarian reserve:</li><li>\u2022 Polycystic Ovary Disease (PCOD) and Hyperstimulation Syndrome: >10 ng/mL</li><li>\u2022 Polycystic Ovary Disease (PCOD) and Hyperstimulation Syndrome:</li><li>\u2022 Tests for ovarian reserve:</li><li>\u2022 Tests for ovarian reserve:</li><li>\u2022 FSH levels: Measured in the early follicular phase (Day 2 or 3 of the menstrual cycle). High FSH means the ovarian reserve is getting depleted. Serum estradiol values: Measured on day 3 of the cycle. Serum estradiol >75 pg/mL indicates ovarian hypofunction. Antral follicular count on ultrasound: Counts less than 4-5 on days 2-5 denote poor response to hormones. Inhibin B: Values <40 pg/mL indicate poor reserve.</li><li>\u2022 FSH levels: Measured in the early follicular phase (Day 2 or 3 of the menstrual cycle). High FSH means the ovarian reserve is getting depleted.</li><li>\u2022 FSH levels:</li><li>\u2022 Serum estradiol values: Measured on day 3 of the cycle. Serum estradiol >75 pg/mL indicates ovarian hypofunction.</li><li>\u2022 Serum estradiol values:</li><li>\u2022 Antral follicular count on ultrasound: Counts less than 4-5 on days 2-5 denote poor response to hormones.</li><li>\u2022 Antral follicular count on ultrasound:</li><li>\u2022 Inhibin B: Values <40 pg/mL indicate poor reserve.</li><li>\u2022 Inhibin B:</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Luteal phase LH: Not a reliable measure of ovarian reserve.</li><li>\u2022 Option A. Luteal phase LH:</li><li>\u2022 Option B. Post luteal phase LH: Not a reliable measure of ovarian reserve.</li><li>\u2022 Option B. Post luteal phase LH:</li><li>\u2022 Option C. FSH in the follicular phase: While useful, it is less reliable than AMH for assessing ovarian reserve.</li><li>\u2022 Option C. FSH in the follicular phase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-Mullerian Hormone (AMH) is the best marker of ovarian reserve as it can be tested on any day of the menstrual cycle and provides a reliable measure of the ovarian reserve.</li><li>\u27a4 Ref: Dutta\u2019s textbook of gynecology 6 th edition Pg 528,529, William\u2019s textbook of gynecology 3 rd edition pg435</li><li>\u27a4 Ref: Dutta\u2019s textbook of gynecology 6 th edition Pg 528,529, William\u2019s textbook of gynecology 3 rd edition pg435</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6340e312",
      "audio": ""
    },
    {
      "text": "An 18-year-old girl presented with amenorrhea. On examination, she had normal genitalia & normal breast development. Her tests reveal a 5 alpha-reductase deficiency. What could be the probable diagnosis? (INICET NOV 2021)",
      "options": [
        {
          "label": "A",
          "text": "Concealed sex",
          "correct": false
        },
        {
          "label": "B",
          "text": "True hermaphroditism",
          "correct": false
        },
        {
          "label": "C",
          "text": "Female pseudohermaphrodite",
          "correct": false
        },
        {
          "label": "D",
          "text": "Male pseudohermaphrodite",
          "correct": true
        }
      ],
      "correct_answer": "D. Male pseudohermaphrodite",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Male pseudohermaphrodite</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Male pseudohermaphroditism involves male gonads with female external genitalia. In 5 alpha-reductase deficiency, there is a failure of the testis to descend and ill development of the penis, resulting in a female phenotype despite having male internal genitalia.</li><li>\u27a4 Ref: Dutta\u2019s textbook of gynecology  6 th edition pg 443</li><li>\u27a4 Ref: Dutta\u2019s textbook of gynecology  6 th edition pg 443</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "64b3b581",
      "audio": ""
    },
    {
      "text": "What hormones are secreted by the Leydig cells and the Sertoli cells respectively? (FMGE JULY 2023)",
      "options": [
        {
          "label": "A",
          "text": "DHA and testosterone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Testosterone and AMH",
          "correct": true
        },
        {
          "label": "C",
          "text": "Testosterone and DHA",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhibin and testosterone",
          "correct": false
        }
      ],
      "correct_answer": "B. Testosterone and AMH",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Testosterone and AMH</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Leydig cells secrete testosterone Sertoli cells secrete Anti-Mullerian Hormone (AMH) and Inhibin</li><li>\u27a4 Leydig cells secrete testosterone</li><li>\u27a4 Sertoli cells secrete Anti-Mullerian Hormone (AMH) and Inhibin</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9157b2cc",
      "audio": ""
    },
    {
      "text": "Which of the following graphs represents normal response to OGTT? (INICET MAY 2022)",
      "options": [
        {
          "label": "A",
          "text": "Graph A",
          "correct": false
        },
        {
          "label": "B",
          "text": "\ufeff\ufeff\ufeffGraph B",
          "correct": false
        },
        {
          "label": "C",
          "text": "\ufeff\ufeff\ufeffGraph C",
          "correct": false
        },
        {
          "label": "D",
          "text": "\ufeff\ufeff\ufeffGraph D",
          "correct": true
        }
      ],
      "correct_answer": "D. \ufeff\ufeff\ufeffGraph D",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_QetTw5P.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Graph D</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The normal response to an Oral Glucose Tolerance Test (OGTT) is depicted by Graph D. During an OGTT, a patient ingests a specified amount of glucose (commonly 75 grams), and blood glucose levels are measured at intervals to evaluate how well the body handles glucose. In a normal response:</li><li>\u2022 Blood glucose levels rise to a peak within 1 hour after ingestion. Glucose levels then decline and return to baseline by 2 hours. The glucose levels do not exceed the renal threshold at any point during the test.</li><li>\u2022 Blood glucose levels rise to a peak within 1 hour after ingestion.</li><li>\u2022 Glucose levels then decline and return to baseline by 2 hours.</li><li>\u2022 The glucose levels do not exceed the renal threshold at any point during the test.</li><li>\u2022 This pattern reflects the body's effective regulation of blood glucose levels and the normal function of insulin.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Graph A: Graph A might depict an abnormal glucose tolerance curve, such as one seen in impaired glucose tolerance or gestational diabetes, where glucose levels remain elevated for a prolonged period or fail to return to baseline.</li><li>\u2022 Option A. Graph A:</li><li>\u2022 Option B. Graph B : Graph B could show a response with an abnormal peak or delayed return to baseline, indicative of glucose intolerance or a diagnostic criterion for diabetes mellitus.</li><li>\u2022 Option B. Graph B</li><li>\u2022 Option C. Graph C : Graph C might represent an exaggerated glucose peak or prolonged elevated glucose levels, suggesting a pathological glucose tolerance response consistent with diabetes.</li><li>\u2022 Option C. Graph C</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A normal OGTT response features a peak in blood glucose levels within 1 hour, followed by a return to baseline levels within 2 hours, without exceeding the renal threshold.</li><li>\u27a4 Ref: https://www.researchgate.net/publication/301045468_VARIANTS_OF_ORAL_GLUCOSE_TOLERANCE_TEST_OGTT_CURVE_IN_GESTATIONAL_DIABETES_MELLITUS_GDM</li><li>\u27a4 Ref:</li><li>\u27a4 https://www.researchgate.net/publication/301045468_VARIANTS_OF_ORAL_GLUCOSE_TOLERANCE_TEST_OGTT_CURVE_IN_GESTATIONAL_DIABETES_MELLITUS_GDM</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fd6fec66",
      "audio": ""
    },
    {
      "text": "A woman presents with dysuria and yellowish discharge. Gram staining shows gram-negative diplococci. What is the diagnosis? (INICET MAY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Trichomoniasis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Neisseria",
          "correct": true
        },
        {
          "label": "C",
          "text": "Chlamydia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bacterial vaginosis",
          "correct": false
        }
      ],
      "correct_answer": "B. Neisseria",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Neisseria</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The identification of gram-negative diplococci in a patient with dysuria and yellowish discharge is highly indicative of Neisseria gonorrhoeae infection, a common cause of gonorrhea</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d641b3a4",
      "audio": ""
    },
    {
      "text": "When is suction and evacuation done? (FMGE JULY 2023)",
      "options": [
        {
          "label": "A",
          "text": "12 weeks",
          "correct": true
        },
        {
          "label": "B",
          "text": "15 weeks",
          "correct": false
        },
        {
          "label": "C",
          "text": "6 weeks",
          "correct": false
        },
        {
          "label": "D",
          "text": "18 weeks",
          "correct": false
        }
      ],
      "correct_answer": "A. 12 weeks",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 12 weeks</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Suction and evacuation, also known as dilation and evacuation (D&E), is a common surgical method for medical termination of pregnancy. This procedure is typically performed up to 12 weeks of gestation (esp. for 9-12 weeks).</li><li>\u2022 The process involves:</li><li>\u2022 Dilation of the cervix : This can be achieved mechanically using instruments like Hegar's dilators or medically with misoprostol. Evacuation of uterine contents : This is done using a suction machine, which can be either a manual vacuum aspirator (MVA) or an electric vacuum aspirator (EVA). In some cases, ovum forceps may also be used to assist in the evacuation.</li><li>\u2022 Dilation of the cervix : This can be achieved mechanically using instruments like Hegar's dilators or medically with misoprostol.</li><li>\u2022 Dilation of the cervix</li><li>\u2022 Evacuation of uterine contents : This is done using a suction machine, which can be either a manual vacuum aspirator (MVA) or an electric vacuum aspirator (EVA). In some cases, ovum forceps may also be used to assist in the evacuation.</li><li>\u2022 Evacuation of uterine contents</li><li>\u2022 Medical methods of termination are usually preferred between 5 to 9 weeks of gestation. After 9 weeks, surgical methods like suction and evacuation become more effective and are the preferred option.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. 15 weeks : Beyond the recommended period for suction and evacuation; other methods may be considered.</li><li>\u2022 Option B. 15 weeks</li><li>\u2022 Option C. 6 weeks : Medical methods are often preferred at this early stage, though suction and evacuation can be performed.</li><li>\u2022 Option C. 6 weeks</li><li>\u2022 Option D. 18 weeks : Typically, more advanced surgical methods or induction of labor would be considered for termination at this stage.</li><li>\u2022 Option D. 18 weeks</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Suction and evacuation is best performed up to 12 weeks of gestation, making it the preferred surgical method for early medical termination of pregnancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d0909bfa",
      "audio": ""
    },
    {
      "text": "In a Partogram, where do you start plotting the cervical dilatation? (INICET NOV 2017)",
      "options": [
        {
          "label": "A",
          "text": "On the action line",
          "correct": false
        },
        {
          "label": "B",
          "text": "Before the action line",
          "correct": false
        },
        {
          "label": "C",
          "text": "On the alert line",
          "correct": true
        },
        {
          "label": "D",
          "text": "After the alert line",
          "correct": false
        }
      ],
      "correct_answer": "C. On the alert line",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) On the alert line</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In the WHO modified partograph, labor progression is charted using alert and action lines. The cervical dilatation is plotted starting in the active phase of labor, typically at 4 cm dilation.</li><li>\u2022 Alert Line : Represents a cervical dilation rate of 1 cm per hour. The first marking of cervical dilatation should be on this line. Action Line : Plotted 4 hours to the right of the alert line. It indicates when intervention should be considered if labor is not progressing as expected.</li><li>\u2022 Alert Line : Represents a cervical dilation rate of 1 cm per hour. The first marking of cervical dilatation should be on this line.</li><li>\u2022 Alert Line</li><li>\u2022 Action Line : Plotted 4 hours to the right of the alert line. It indicates when intervention should be considered if labor is not progressing as expected.</li><li>\u2022 Action Line</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. On the action line: Plotting starts on the alert line, not the action line. The action line is used for intervention planning.</li><li>\u2022 Option A. On the action line:</li><li>\u2022 Option B. Before the action line: This is incorrect as the plotting starts on the alert line.</li><li>\u2022 Option B. Before the action line:</li><li>\u2022 Option D. After the alert line: This is incorrect since plotting should start on the alert line.</li><li>\u2022 Option D. After the alert line:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a Partogram, cervical dilatation is first plotted on the alert line, which indicates the expected rate of progress in labor.</li><li>\u27a4 Ref: https://iris.who.int/bitstream/handle/10665/337693/9789240017566-eng.pdf</li><li>\u27a4 Ref:</li><li>\u27a4 https://iris.who.int/bitstream/handle/10665/337693/9789240017566-eng.pdf</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9bb181a3",
      "audio": ""
    },
    {
      "text": "Where will be the level of the uterus on the second-day post-delivery? (NEET PG 2022)",
      "options": [
        {
          "label": "A",
          "text": "One finger breadth below umbilicus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Two finger breadths below umbilicus",
          "correct": true
        },
        {
          "label": "C",
          "text": "Three finger breadths below umbilicus",
          "correct": false
        },
        {
          "label": "D",
          "text": "Four finger breadths below umbilicus",
          "correct": false
        }
      ],
      "correct_answer": "B. Two finger breadths below umbilicus",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Two finger breadths below umbilicus</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The uterus will be two finger breadths below umbilicus on the second-day post-delivery.</li><li>\u27a4 two finger breadths below umbilicus</li><li>\u27a4 Ref: Page no 169, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li><li>\u27a4 Ref: Page no 169, DC Dutta\u2019s Textbook of Obstetrics, 8 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e447ea5c",
      "audio": ""
    },
    {
      "text": "A baby was born at 34 weeks of pregnancy; the appearance of the baby is given below. What is the mother suffering from? (NEET PG 2019)",
      "options": [
        {
          "label": "A",
          "text": "Gestational diabetes",
          "correct": true
        },
        {
          "label": "B",
          "text": "\ufeff\ufeff\ufeffRubella",
          "correct": false
        },
        {
          "label": "C",
          "text": "\ufeff\ufeff\ufeffHypothyroidism",
          "correct": false
        },
        {
          "label": "D",
          "text": "\ufeff\ufeff\ufeffGestational hypertension",
          "correct": false
        }
      ],
      "correct_answer": "A. Gestational diabetes",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/picture7.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Gestational diabetes</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The image shows a large for gestational age (LGA) fetus. Macrosomia is a condition where a newborn baby is significantly larger than average. This can often be identified by a higher birth weight and size compared to typical babies born at the same gestational age.</li><li>\u2022 Causes of Macrosomia:</li><li>\u2022 Causes of Macrosomia:</li><li>\u2022 Gestational Diabetes Mellitus (GDM) and Overt Diabetes Mellitus: Maternal hyperglycemia leads to fetal hyperglycemia, which stimulates insulin production in the fetus. Insulin acts as a growth hormone, leading to increased fetal growth and fat deposition. Maternal Obesity: Increased maternal body mass index (BMI) is associated with a higher risk of delivering a macrosomic baby. Previous Baby with Macrosomia: A history of delivering a large baby increases the risk of subsequent babies also being large. Post-term Pregnancy: Pregnancy extending beyond the due date increases the chance of the baby growing larger. Excessive Weight Gain in Pregnancy: Significant maternal weight gain during pregnancy contributes to larger fetal size.</li><li>\u2022 Gestational Diabetes Mellitus (GDM) and Overt Diabetes Mellitus: Maternal hyperglycemia leads to fetal hyperglycemia, which stimulates insulin production in the fetus. Insulin acts as a growth hormone, leading to increased fetal growth and fat deposition.</li><li>\u2022 Gestational Diabetes Mellitus (GDM) and Overt Diabetes Mellitus:</li><li>\u2022 Maternal hyperglycemia leads to fetal hyperglycemia, which stimulates insulin production in the fetus. Insulin acts as a growth hormone, leading to increased fetal growth and fat deposition.</li><li>\u2022 Maternal hyperglycemia leads to fetal hyperglycemia, which stimulates insulin production in the fetus. Insulin acts as a growth hormone, leading to increased fetal growth and fat deposition.</li><li>\u2022 Maternal Obesity: Increased maternal body mass index (BMI) is associated with a higher risk of delivering a macrosomic baby.</li><li>\u2022 Maternal Obesity:</li><li>\u2022 Increased maternal body mass index (BMI) is associated with a higher risk of delivering a macrosomic baby.</li><li>\u2022 Increased maternal body mass index (BMI) is associated with a higher risk of delivering a macrosomic baby.</li><li>\u2022 Previous Baby with Macrosomia: A history of delivering a large baby increases the risk of subsequent babies also being large.</li><li>\u2022 Previous Baby with Macrosomia:</li><li>\u2022 A history of delivering a large baby increases the risk of subsequent babies also being large.</li><li>\u2022 A history of delivering a large baby increases the risk of subsequent babies also being large.</li><li>\u2022 Post-term Pregnancy: Pregnancy extending beyond the due date increases the chance of the baby growing larger.</li><li>\u2022 Post-term Pregnancy:</li><li>\u2022 Pregnancy extending beyond the due date increases the chance of the baby growing larger.</li><li>\u2022 Pregnancy extending beyond the due date increases the chance of the baby growing larger.</li><li>\u2022 Excessive Weight Gain in Pregnancy: Significant maternal weight gain during pregnancy contributes to larger fetal size.</li><li>\u2022 Excessive Weight Gain in Pregnancy:</li><li>\u2022 Significant maternal weight gain during pregnancy contributes to larger fetal size.</li><li>\u2022 Significant maternal weight gain during pregnancy contributes to larger fetal size.</li><li>\u2022 Conditions Not Associated with Macrosomia:</li><li>\u2022 Conditions Not Associated with Macrosomia:</li><li>\u2022 Anemia and Antepartum Hemorrhage (APH): These conditions are typically associated with fetal growth restriction rather than macrosomia. Thrombocytopenia: This condition has no direct association with fetal weight.</li><li>\u2022 Anemia and Antepartum Hemorrhage (APH): These conditions are typically associated with fetal growth restriction rather than macrosomia.</li><li>\u2022 Anemia and Antepartum Hemorrhage (APH):</li><li>\u2022 Thrombocytopenia: This condition has no direct association with fetal weight.</li><li>\u2022 Thrombocytopenia:</li><li>\u2022 Other Options</li><li>\u2022 Other Options</li><li>\u2022 Option B. Rubella: Rubella infection during pregnancy can cause congenital rubella syndrome, which is typically associated with intrauterine growth restriction (IUGR), not macrosomia.</li><li>\u2022 Option B. Rubella:</li><li>\u2022 Option C. Hypothyroidism: Maternal hypothyroidism can lead to complications such as preterm birth and low birth weight but is not directly linked to macrosomia.</li><li>\u2022 Option C. Hypothyroidism:</li><li>\u2022 Option D. Gestational Hypertension: Gestational hypertension is associated with IUGR and preterm birth rather than increased fetal size.</li><li>\u2022 Option D. Gestational Hypertension:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Gestational diabetes is a significant risk factor for macrosomia, leading to the birth of large for gestational age (LGA) babies.</li><li>\u27a4 Ref: Page no 2169, Williams Obstetrics 26 th edition</li><li>\u27a4 Ref: Page no 2169, Williams Obstetrics 26 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c772e52a",
      "audio": ""
    },
    {
      "text": "A 16-year-old girl with primary amenorrhea has the following features. What is the most probable diagnosis? (NEET PG 2018) Normal stature Thelarche - absent FSH, LH - high Karyotype - 46 XX",
      "options": [
        {
          "label": "A",
          "text": "Testicular feminizing syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gonadal dysgenesis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Kallmann syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Turner syndrome",
          "correct": false
        }
      ],
      "correct_answer": "B. Gonadal dysgenesis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Gonadal dysgenesis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The probable diagnosis in this case is pure gonadal dysgenesis. Primary amenorrhea with absent secondary sexual characteristics (thelarche) and high levels of FSH and LH indicate hypergonadotropic hypogonadism, which suggests an ovarian cause. The karyotype 46 XX confirms gonadal dysgenesis.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Testicular feminizing syndrome/Androgen Insensitivity Syndrome</li><li>\u2022 Option A. Testicular feminizing syndrome/Androgen Insensitivity Syndrome</li><li>\u2022 This condition occurs in individuals with a 46 XY karyotype. Individuals with this syndrome have absent uterus and ovaries and exhibit secondary sexual development, especially breast development, due to peripheral production of estrogens.</li><li>\u2022 This condition occurs in individuals with a 46 XY karyotype.</li><li>\u2022 Individuals with this syndrome have absent uterus and ovaries and exhibit secondary sexual development, especially breast development, due to peripheral production of estrogens.</li><li>\u2022 Option C. Kallmann Syndrome</li><li>\u2022 Option C. Kallmann Syndrome</li><li>\u2022 This is a cause of hypogonadotropic hypogonadism leading to primary amenorrhea. It is associated with anosmia and absent secondary sexual characteristics. FSH and LH levels are low in this condition.</li><li>\u2022 This is a cause of hypogonadotropic hypogonadism leading to primary amenorrhea.</li><li>\u2022 It is associated with anosmia and absent secondary sexual characteristics.</li><li>\u2022 FSH and LH levels are low in this condition.</li><li>\u2022 Option D. Turner Syndrome</li><li>\u2022 Option D. Turner Syndrome</li><li>\u2022 Characterized by a 45 XO karyotype. Individuals have streak ovaries leading to low estrogen levels and absent secondary sexual characteristics. FSH and LH levels are high. A very important feature is short stature, which is not seen in the patient described.</li><li>\u2022 Characterized by a 45 XO karyotype.</li><li>\u2022 Individuals have streak ovaries leading to low estrogen levels and absent secondary sexual characteristics.</li><li>\u2022 FSH and LH levels are high.</li><li>\u2022 A very important feature is short stature, which is not seen in the patient described.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Primary amenorrhea with high FSH and LH levels and a 46 XX karyotype indicates gonadal dysgenesis.</li><li>\u27a4 Ref: Page no 454, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li><li>\u27a4 Ref: Page no 454, DC Dutta\u2019s Textbook of Gynecology, 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "957acb31",
      "audio": ""
    },
    {
      "text": "Puerperal pyrexia is defined as: (FMGE JULY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Temp > 100.4\u00b0F occurring 48h after delivery",
          "correct": false
        },
        {
          "label": "B",
          "text": "Temp > 100.4\u00b0F occurring 24h after delivery",
          "correct": true
        },
        {
          "label": "C",
          "text": "Temp > 100.4\u00b0F occurring 12h after delivery",
          "correct": false
        },
        {
          "label": "D",
          "text": "Temp > 100.4\u00b0F occurring 6h after delivery",
          "correct": false
        }
      ],
      "correct_answer": "B. Temp > 100.4\u00b0F occurring 24h after delivery",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Puerperal pyrexia is defined as a temperature greater than 100.4\u00b0F occurring 24 hours after delivery, indicating postpartum infection or other complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "88d91973",
      "audio": ""
    },
    {
      "text": "The given image depicts: (INICET NOV 2022)",
      "options": [
        {
          "label": "A",
          "text": "Succenturiate lobe",
          "correct": false
        },
        {
          "label": "B",
          "text": "\ufeff\ufeff\ufeffVelamentous insertion of the cord",
          "correct": false
        },
        {
          "label": "C",
          "text": "\ufeff\ufeff\ufeffBoth succenturiate lobe and velamentous insertion",
          "correct": true
        },
        {
          "label": "D",
          "text": "\ufeff\ufeff\ufeffNormal placenta",
          "correct": false
        }
      ],
      "correct_answer": "C. \ufeff\ufeff\ufeffBoth succenturiate lobe and velamentous insertion",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/03/inicet-obg-nov-2022-1.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Both succenturiate lobe and velamentous insertion</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Succenturiate lobe : This refers to a placenta with one or more accessory lobes connected to the main part of the placenta by blood vessels. It is characterized by the presence of a smaller, separate lobe in addition to the main placental mass. Velamentous insertion of the cord : This occurs when the umbilical cord inserts into the fetal membranes (chorioamnion) rather than directly into the placental mass. The vessels then travel through the membranes to reach the placenta, making them vulnerable to rupture. The image shows both conditions: a smaller accessory lobe (succenturiate lobe) and the cord inserting into the membranes rather than the placenta (velamentous insertion).</li><li>\u2022 Succenturiate lobe : This refers to a placenta with one or more accessory lobes connected to the main part of the placenta by blood vessels. It is characterized by the presence of a smaller, separate lobe in addition to the main placental mass.</li><li>\u2022 Succenturiate lobe</li><li>\u2022 Velamentous insertion of the cord : This occurs when the umbilical cord inserts into the fetal membranes (chorioamnion) rather than directly into the placental mass. The vessels then travel through the membranes to reach the placenta, making them vulnerable to rupture.</li><li>\u2022 Velamentous insertion of the cord</li><li>\u2022 The image shows both conditions: a smaller accessory lobe (succenturiate lobe) and the cord inserting into the membranes rather than the placenta (velamentous insertion).</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Succenturiate lobe : This option is partially correct but does not account for the velamentous insertion.</li><li>\u2022 Option A. Succenturiate lobe</li><li>\u2022 Option B. Velamentous insertion of the cord : This option is partially correct but does not account for the succenturiate lobe.</li><li>\u2022 Option B. Velamentous insertion of the cord</li><li>\u2022 Option D. Normal placenta : This is incorrect as the image shows abnormalities not seen in a normal placenta.</li><li>\u2022 Option D. Normal placenta</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A placenta with both a succenturiate lobe and velamentous insertion of the cord is characterized by the presence of a smaller accessory lobe and the umbilical cord inserting into the fetal membranes.</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 24 th edition pg122, 117, Dutta\u2019s textbook of obstetrics 8 th edition pg 251,253</li><li>\u27a4 Ref: William\u2019s textbook of obstetrics 24 th edition pg122, 117, Dutta\u2019s textbook of obstetrics 8 th edition pg 251,253</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7892575d",
      "audio": ""
    },
    {
      "text": "A patient was undergoing a hysteroscopic removal of a submucosal fibroid, in which a fluid deficit of 2000 mL is estimated in a patient. What is the immediate complication of this? (NEET PG 2023)",
      "options": [
        {
          "label": "A",
          "text": "Acute tubular necrosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "DIC",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pulmonary edema",
          "correct": true
        },
        {
          "label": "D",
          "text": "Thromboembolism",
          "correct": false
        }
      ],
      "correct_answer": "C. Pulmonary edema",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Pulmonary edema</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The given clinical scenario depicts case of fluid overload, due to which pulmonary edema can develop.</li><li>\u2022 During hysteroscopy, systemic absorption of uterine distension fluid occurs through open sinuses or vessels. Fluid deficit can be estimated by manual calculation or by use of an automated fluid management system. When using hypotonic solutions (like glycine), the maximum allowed fluid deficit is 1000mL for healthy patients and 750mL for elderly patients or those with medical comorbidities. For normal saline, the maximum allowed fluid deficit is 2,500mL for healthy patients and 750mL for those with cardiovascular disease. If excessive absorption of fluid occurs with a hypotonic fluid; obtain serum electrolytes and the patient should be evaluated for volume overload. Asymptomatic hyponatremia can be treated with fluid restriction and careful monitoring of urine output. Treatment of symptomatic hyponatremia requires infusion of 3% sodium chloride and managed in intensive care. Fluid overload from normal saline can be managed by fluid restriction; IV furosemide (20-40mg) is indicated if there is clinical or radiological evidence of pulmonary edema</li><li>\u2022 During hysteroscopy, systemic absorption of uterine distension fluid occurs through open sinuses or vessels.</li><li>\u2022 Fluid deficit can be estimated by manual calculation or by use of an automated fluid management system.</li><li>\u2022 When using hypotonic solutions (like glycine), the maximum allowed fluid deficit is 1000mL for healthy patients and 750mL for elderly patients or those with medical comorbidities.</li><li>\u2022 For normal saline, the maximum allowed fluid deficit is 2,500mL for healthy patients and 750mL for those with cardiovascular disease.</li><li>\u2022 If excessive absorption of fluid occurs with a hypotonic fluid; obtain serum electrolytes and the patient should be evaluated for volume overload.</li><li>\u2022 Asymptomatic hyponatremia can be treated with fluid restriction and careful monitoring of urine output.</li><li>\u2022 Treatment of symptomatic hyponatremia requires infusion of 3% sodium chloride and managed in intensive care.</li><li>\u2022 Fluid overload from normal saline can be managed by fluid restriction; IV furosemide (20-40mg) is indicated if there is clinical or radiological evidence of pulmonary edema</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option A. Acute tubular necrosis: While fluid overload can contribute to kidney injury, acute tubular necrosis is not the immediate complication in this scenario.</li><li>\u2022 Option A. Acute tubular necrosis:</li><li>\u2022 Option B. DIC: Disseminated intravascular coagulation is a serious condition involving abnormal blood clotting but is not directly related to fluid overload from hysteroscopy.</li><li>\u2022 Option B. DIC:</li><li>\u2022 Option D. Thromboembolism: Thromboembolism involves blood clots traveling to various parts of the body but is not the immediate consequence of fluid overload.</li><li>\u2022 Option D. Thromboembolism:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fluid overload during hysteroscopic surgery can lead to pulmonary edema as an immediate complication due to excessive absorption of uterine distension fluid.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "59f75a26",
      "audio": ""
    },
    {
      "text": "A patient developed atonic postpartum hemorrhage after a normal vaginal delivery. She was shifted to the OT and the obstetrician planned ligation of vessels to arrest the bleeding. What is the order of ligation of the blood vessels supplying the uterus? (NEET PG 2021)",
      "options": [
        {
          "label": "A",
          "text": "Uterine artery - Ovarian artery - Internal iliac artery",
          "correct": true
        },
        {
          "label": "B",
          "text": "Uterine artery - Ovarian artery- External iliac artery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Uterine artery - Ovarian artery - Vaginal artery",
          "correct": false
        },
        {
          "label": "D",
          "text": "Uterine artery - pudendal artery - Vaginal artery",
          "correct": false
        }
      ],
      "correct_answer": "A. Uterine artery - Ovarian artery - Internal iliac artery",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Uterine artery \u2013 Ovarian artery \u2013 Internal iliac artery</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The stepwise devascularization approach for managing atonic postpartum hemorrhage includes ligation of the uterine arteries, ovarian arteries, and anterior division of the internal iliac arteries in that specific order.</li><li>\u27a4 Ref: Page no 2023, Williams Obstetrics 26 th edition</li><li>\u27a4 Ref: Page no 2023, Williams Obstetrics 26 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "468c5cf9",
      "audio": ""
    },
    {
      "text": "A chorionic villous sampling is done at 12 weeks in a woman whose blood group is B negative. Her husband's blood group is A positive. What is the dose of Anti D given? (FMGE JANUARY 2024)",
      "options": [
        {
          "label": "A",
          "text": "50",
          "correct": true
        },
        {
          "label": "B",
          "text": "100",
          "correct": false
        },
        {
          "label": "C",
          "text": "150",
          "correct": false
        },
        {
          "label": "D",
          "text": "300",
          "correct": false
        }
      ],
      "correct_answer": "A. 50",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/07/screenshot-2024-06-07-125324.png"
      ],
      "explanation": "<p><strong>Ans. A) 50</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In the case of Rh incompatibility, where the mother is Rh-negative (B negative) and the father is Rh-positive (A positive), there is a risk of fetal-maternal hemorrhage (FMH) during invasive procedures like chorionic villous sampling (CVS). This can lead to the mixing of fetal and maternal blood, potentially causing the mother to form antibodies against the Rh-positive fetal red blood cells. To prevent this alloimmunization, an Anti-D immunoglobulin injection is administered.</li><li>\u2022 The standard practice is to give Anti-D immunoglobulin during any inciting event (e.g., CVS, amniocentesis, abdominal trauma, abruption, placenta previa) and at delivery. Additionally, it is given prophylactically at 28 weeks of gestation to all Rh-negative women.</li><li>\u2022 The dosage of Anti-D depends on the gestational age:</li><li>\u2022 Less than 12 weeks: 50 micrograms intramuscularly.</li><li>\u2022 More than 12 weeks: 300 micrograms intramuscularly.</li><li>\u2022 Since the CVS was performed at 12 weeks, the appropriate dose of Anti-D is 50 micrograms.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 For Rh-negative women undergoing an inciting event like chorionic villous sampling at less than 12 weeks gestation, the dose of Anti-D given is 50 micrograms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d188d6b5",
      "audio": ""
    },
    {
      "text": "What is the most useful test in vesicovaginal fistula? (INICET MAY 2018)",
      "options": [
        {
          "label": "A",
          "text": "Cystoscopy",
          "correct": true
        },
        {
          "label": "B",
          "text": "3 swab test",
          "correct": false
        },
        {
          "label": "C",
          "text": "MRI",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cystometry",
          "correct": false
        }
      ],
      "correct_answer": "A. Cystoscopy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Cystoscopy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Cystoscopy is the most useful test for diagnosing vesicovaginal fistula (VVF). It allows direct visualization of the bladder and can help identify the exact location, size, and number of fistulas. Additionally, cystoscopy can be used to assess the bladder for any associated injuries or other abnormalities.</li><li>\u2022 Other options:</li><li>\u2022 Other options:</li><li>\u2022 Option B. 3 swab test: This test is used to identify the type of genitourinary fistula (vesicovaginal or ureterovaginal) but is not as specific as cystoscopy for visualizing the fistula directly.</li><li>\u2022 Option B. 3 swab test:</li><li>\u2022 Option C. MRI: While MRI can provide detailed images of the pelvic structures and help in the diagnosis of fistulas, it is not the first-line investigation. It is more useful in complex cases or when additional information is needed.</li><li>\u2022 Option C. MRI:</li><li>\u2022 Option D. Cystometry: This test evaluates bladder filling and voiding problems and is not specific for diagnosing vesicovaginal fistula.</li><li>\u2022 Option D. Cystometry:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Cystoscopy is the most useful test for directly visualizing vesicovaginal fistulas, determining their size, location, and number, and assessing the bladder for any associated injuries.</li><li>\u27a4 Ref: Page no 417, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li><li>\u27a4 Ref: Page no 417, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2bdcd316",
      "audio": ""
    },
    {
      "text": "A 28-year-old married woman who is anxious to conceive presents with copious vaginal discharge, without any itching. Her last menstrual period was 13 days ago. What is the cause of her vaginal discharge? (NEET PG 2021)",
      "options": [
        {
          "label": "A",
          "text": "Candidiasis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bacterial vaginosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trichomoniasis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Physiological",
          "correct": true
        }
      ],
      "correct_answer": "D. Physiological",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/7_SZ5qvMl.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Physiological</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Physiological vaginal discharge is typically clear or white, without odor or itching, and can occur at ovulation, puberty, pregnancy, or occasionally during the premenstrual phase.</li><li>\u27a4 Ref: Page no 554, DC Dutta\u2019s Textbook of gynecology 6 th edition</li><li>\u27a4 Ref: Page no 554, DC Dutta\u2019s Textbook of gynecology 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6ee5dee7",
      "audio": ""
    },
    {
      "text": "Kassowitz rule is related to? (INICET MAY 2022)",
      "options": [
        {
          "label": "A",
          "text": "Primary syphilis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Congenital syphilis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Secondary syphilis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Latent syphilis",
          "correct": false
        }
      ],
      "correct_answer": "B. Congenital syphilis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Congenital syphilis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Kassowitz's rule pertains to congenital syphilis. According to this rule, if a woman with untreated syphilis has multiple pregnancies, the likelihood of congenital syphilis affecting the fetus in later pregnancies decreases. This phenomenon is observed as a result of the immune system's adaptive response and potential changes in the transmission dynamics of the infection over successive pregnancies. Therefore, the rule suggests that with each subsequent pregnancy, the outcome for the fetus improves if the infection remains untreated.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Primary syphilis : Primary syphilis involves the initial chancre or ulcer at the site of infection and is not related to Kassowitz's rule, which specifically addresses outcomes in congenital syphilis.</li><li>\u2022 Option A. Primary syphilis</li><li>\u2022 Option C. Secondary syphilis : Secondary syphilis is characterized by systemic manifestations such as skin rashes and mucous membrane lesions and is not related to Kassowitz's rule.</li><li>\u2022 Option C. Secondary syphilis</li><li>\u2022 Option D. Latent syphilis : Latent syphilis refers to a stage where no symptoms are present but the infection is still systemic. Kassowitz's rule is not associated with latent syphilis.</li><li>\u2022 Option D. Latent syphilis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Kassowitz rule states that the likelihood of congenital syphilis infection decreases with each successive pregnancy in a woman with untreated syphilis.</li><li>\u27a4 Ref: Page no 343, DC Dutta\u2019s Textbook of Obstetrics 8 th edition</li><li>\u27a4 Ref: Page no 343, DC Dutta\u2019s Textbook of Obstetrics 8 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "461e60ad",
      "audio": ""
    },
    {
      "text": "As per Anemia Mukt Bharat, which is the correct statement regarding iron prophylaxis in pregnant women? (FMGE JULY 2024)",
      "options": [
        {
          "label": "A",
          "text": "Iron prophylaxis is given for 6 months antepartum and 6 months postpartum",
          "correct": true
        },
        {
          "label": "B",
          "text": "Iron prophylaxis is started at 14 weeks and continued for 6 weeks after delivery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Iron prophylaxis starts in the 1st trimester and continues till 6 weeks postpartum",
          "correct": false
        },
        {
          "label": "D",
          "text": "Iron prophylaxis is given 6 months antepartum and 3 months postpartum",
          "correct": false
        }
      ],
      "correct_answer": "A. Iron prophylaxis is given for 6 months antepartum and 6 months postpartum",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Iron prophylaxis is given for 6 months antepartum and 6 months postpartum</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Anemia Mukt Bharat (AMB) initiative outlines that iron prophylaxis for pregnant women should start from the 14th week of pregnancy and continue throughout the pregnancy (approximately 6 months) and for 6 months postpartum. The recommended dosage is one red-colored, sugar-coated tablet containing 60 mg of elemental iron and 0.5 mg of folic acid daily. This regimen helps in preventing iron deficiency anemia and folate deficiency anemia during and after pregnancy.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Iron prophylaxis for pregnant women under the Anemia Mukt Bharat initiative is given from 14 weeks of pregnancy and continues for 6 months postpartum.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d61036bb",
      "audio": ""
    },
    {
      "text": "A pregnant woman has a fetus with Down's syndrome. Triple test done at 15-16 weeks will have? (INICET NOV 2017)",
      "options": [
        {
          "label": "A",
          "text": "Low MSAFP, high hCG, low UE3",
          "correct": true
        },
        {
          "label": "B",
          "text": "High MSAFP, low hCG, high UE3",
          "correct": false
        },
        {
          "label": "C",
          "text": "Low MSAFP, high hCG, high UE3",
          "correct": false
        },
        {
          "label": "D",
          "text": "High MSAFP, low hCG, low UE3",
          "correct": false
        }
      ],
      "correct_answer": "A. Low MSAFP, high hCG, low UE3",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/03/untitled-296.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Low MSAFP, high hCG, low UE3</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The triple and quadruple test is done between 15 \u2013 21 weeks.</li><li>\u2022 Components of Triple test are: Free \u03b2 hCG, unconjugated Estriol (uE3) and Maternal Serum \u03b1-fetoprotein. Components of the Quadruple test are: Free \u03b2 hCG, unconjugated Estriol (uE3), Maternal Serum \u03b1-fetoprotein. And Inhibin A.</li><li>\u2022 Components of Triple test are: Free \u03b2 hCG, unconjugated Estriol (uE3) and Maternal Serum \u03b1-fetoprotein.</li><li>\u2022 Components of the Quadruple test are: Free \u03b2 hCG, unconjugated Estriol (uE3), Maternal Serum \u03b1-fetoprotein. And Inhibin A.</li><li>\u2022 *Easy to remember: B for B ig; so in Down\u2019s syndrome; B eta hCG and Inhi B in A: B ig/ Increased</li><li>\u2022 B</li><li>\u2022 B</li><li>\u2022 B</li><li>\u2022 B</li><li>\u2022 B</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The triple test results for Down's syndrome typically show low MSAFP, high hCG, and low uE3.</li><li>\u27a4 Ref: Page 859, Williams Obstetrics 26 th edition</li><li>\u27a4 Ref: Page 859, Williams Obstetrics 26 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d51b31a",
      "audio": ""
    },
    {
      "text": "What is the best parameter for estimating fetal age during the first trimester using ultrasound? (FMGE JANUARY 2023)",
      "options": [
        {
          "label": "A",
          "text": "Biparietal diameter",
          "correct": false
        },
        {
          "label": "B",
          "text": "Head circumference",
          "correct": false
        },
        {
          "label": "C",
          "text": "Crown rump length",
          "correct": true
        },
        {
          "label": "D",
          "text": "Abdominal circumference",
          "correct": false
        }
      ],
      "correct_answer": "C. Crown rump length",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/19/untitled-1041.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Crown rump length</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Crown rump length is the best parameter for estimating fetal age during the first trimester using ultrasound.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Options A. Biparietal diameter, B. Head circumference and D. Abdominal circumference are parameters useful in second trimester</li><li>\u2022 Options A. Biparietal diameter, B. Head circumference</li><li>\u2022 D.</li><li>\u2022 Abdominal circumference</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Crown rump length is the best parameter for estimating fetal age during the first trimester using ultrasound.</li><li>\u27a4 Ref: Dutta\u2019s Textbook of Obstetrics 8 th Edition page 84</li><li>\u27a4 Ref: Dutta\u2019s Textbook of Obstetrics 8 th Edition page 84</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a519c364",
      "audio": ""
    },
    {
      "text": "A 16-year-old female patient presents with an ovarian mass. On further evaluation, her serum biomarkers are found to be normal except for LDH, which is found to be elevated. The most likely diagnosis is: (INICET NOV 2017)",
      "options": [
        {
          "label": "A",
          "text": "Dysgerminoma",
          "correct": true
        },
        {
          "label": "B",
          "text": "Endodermal sinus tumor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Malignant teratoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mucinous cystadenocarcinoma",
          "correct": false
        }
      ],
      "correct_answer": "A. Dysgerminoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Dysgerminoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The given clinical history of a 16-year-old female presenting with an ovarian mass with raised LDH points towards the diagnosis of dysgerminoma. Dysgerminomas usually arise in young women or in children, with an average incidence at the age of 20. They currently account for approximately one-third of all malignant ovarian germ cell tumors and are the most common malignant ovarian tumors found in pregnancy.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Endodermal sinus tumor: This is typically associated with elevated alpha-fetoprotein (AFP), not LDH.</li><li>\u2022 Option B. Endodermal sinus tumor:</li><li>\u2022 Option C. Malignant teratoma: This type of tumor does not typically present with elevated LDH as the sole abnormal marker.</li><li>\u2022 Option C. Malignant teratoma:</li><li>\u2022 Option D. Mucinous cystadenocarcinoma: This epithelial ovarian tumor is usually associated with elevated CA-125, not LDH.</li><li>\u2022 Option D. Mucinous cystadenocarcinoma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dysgerminoma is the most likely diagnosis in a young female with an ovarian mass and elevated LDH levels.</li><li>\u27a4 Ref: Page no 381, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li><li>\u27a4 Ref: Page no 381, DC Dutta\u2019s Textbook of Gynecology 6 th edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f5d35b5d",
      "audio": ""
    }
  ]
}